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Abstract 
 
 
Sacrococcygeal pilonidal sinus disease (PSD) is a common, painful condition 
affecting 26 per 100,000. Surgical procedures used to treat PSD vary and result in 
either a wound with primary closure or an open wound which heals by secondary 
intention. Because of the anatomical location of these wounds, there is a high risk of 
post-operative infection, which can result in delayed wound healing.  
 
A randomised controlled trial (RCT) was conducted to determine if the prophylactic 
use of nanocrystalline silver alginate dressings could reduce the bacterial burden in 
these wounds and result in faster healing times as compared to calcium alginate 
dressings.  Forty eight participants, who had undergone a surgical incision or 
excision procedure for pilonidal sinus disease, and had a wound healing by 
secondary intention, were recruited to the study.  Participants were randomly 
allocated to receive daily wound care with either a nanocrystalline silver alginate 
dressing or a calcium alginate dressing, until wound healing was achieved or a 
maximum period of 8 weeks. Wounds were assessed and measured at recruitment 
and on a weekly basis to ascertain healing rates. Wound swabs were collected at 
recruitment and weeks 4 and 8 to determine semi-quantitative bacteriology. The cost 
of care was analysed to compare cost of care between the treatment groups. 
 
Although, the nanocrystalline silver alginate dressing group had a mean time to 
wound healing of 46 days as compared to 66 days for the calcium alginate dressing 
group, this was not a significant finding. The silver alginate dressing group had a 
vi 
 
20% greater reduction in wound size over the study period as compared to the 
calcium alginate dressing group. The daily cost of care provision for the silver 
alginate dressing group was higher as compared to the calcium alginate dressing, 
however, there was no difference between the groups for the overall cost of study 
participation or the cost to achieve wound healing, concluding that the silver alginate 
dressing was a cost effective management option for pilonidal sinus wounds healing 
by secondary intention.   
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Chapter 1 
Introduction 
 
Introduction 
Sacrococcygeal pilonidal sinus disease (PSD) is a common, painful condition which 
frequently results in surgical intervention (Miller & Harding, 2003).  It is reported to 
affect 26 per 100,000 (Sondenaa, Anderson, & Soreide, 1992), with males being 
affected three times more frequently than females (Surrell, 1994). Surgical 
procedures used to treat PSD vary and result in either a wound with primary closure 
or an open wound which heals by secondary intention (McCallum, King, & Bruce, 
2007). Post-operative wound infection is a significant risk and results in impaired 
client wellbeing, delayed wound healing and additional health care expenditure 
(Harris & Holloway, 2012; McCallum et al., 2007). The risk of wound infection relates 
to the anatomical location of these wounds and the pathophysiology of this condition, 
as it is often associated with abscess formation (McCallum et al., 2007). Pilonidal 
sinus wounds (PSW) healing by secondary intention can take several months to heal 
(Harris & Holloway, 2012) despite the fact that they commonly affect young 
individuals with low risk factors for delayed wound healing(Harris & Holloway, 2012).  
 
Calcium alginate dressings are commonly used for pilonidal sinus wounds because 
of the haemostatic, low adherence and absorption properties of this dressing product 
(Thomas, 1992). Covert wound infections can be managed with topical antiseptic 
agents in the form of solutions or dressing products however, local or systemic 
infections require systemic treatment with antibiotics (Principles of Best Practice, 
2008). Silver has a broad spectrum of antimicrobial activity and thus is suitable to 
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manage covert wound infection, as bacteria found in wounds are usually of mixed 
species, requiring broad spectrum treatment (Percival, Bowler, & Russell, 2005). 
Despite wounds resulting from PSD being fairly common, there is little documented 
evidence to guide clinicians in their management, especially, when healing becomes 
protracted.  The goal is to achieve wound closure in a timely manner without the 
complications of wound infection or recurrence of the disease (Mohamed, Kadry, & 
Adly, 2005).  
 
Background 
Silver Chain is the largest domiciliary nursing agency in Western Australia (WA) and 
provides home and clinic based services to clients in the WA community.  A major 
component of the nursing services provided by Silver Chain includes management of 
acute and chronic wounds. 
 
Clients with acute surgical wounds resulting from pilonidal sinus disease are 
commonly referred to Silver Chain clinics for management.  In 2005, the researcher 
conducted an audit which revealed that from February 1st, 2005 to January 31st, 
2006, Silver Chain provided wound management to a total of 453 clients with a 
wound relating to pilonidal sinus disease.  The episodes of care for these clients 
ranged from 1 to 424 days with the average length of stay with the nursing 
organisation being 46 days. The average age of the population affected by pilonidal 
sinus disease is 21 years and despite the absence of many factors known to delay 
wound healing in this age group, healing of many of these surgical wounds was 
delayed.  
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Common management of pilonidal sinus wounds within the community setting 
includes daily wound care with a calcium alginate dressing, which is lightly packed 
into the wound cavity to achieve controlled closure of the wound from the base 
upwards. Calcium alginate dressings promote moist wound healing and they assist 
with haemostasis.  Intermittent treatment with a topical antimicrobial agent would be 
implemented should signs and symptoms of overt or covert infection become 
clinically apparent.  
 
Aim 
The purpose of this study was to determine if the prophylactic use of nanocrystalline 
silver alginate dressings, in sacrococcygeal pilonidal sinus wounds healing by 
secondary intention, would promote faster healing as compared to calcium alginate 
dressings.  
 
Objectives 
The specific research objectives were to: 
1. Determine the healing times associated with the prophylactic use of 
nanocrystalline silver alginate dressings and calcium alginate dressings in the 
treatment of sacrococcygeal pilonidal sinus wounds healing by secondary 
intention. 
2. Investigate the antibacterial effectiveness of nanocrystalline silver alginate 
dressings in the management of sacrococcygeal pilonidal sinus wounds. 
3. Evaluate the cost-effectiveness of nanocrystalline silver alginate dressings as 
compared to calcium alginate dressings in the treatment of sacrococcygeal 
pilonidal sinus wounds.  
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Hypothesis 
The prophylactic use of nanocrystalline silver alginate dressings in sacrococcygeal 
wounds, would demonstrate a greater reduction in wound healing time as compared 
to calcium alginate dressings.  
 
Significance of the Study 
There is a dearth of evidence based guidelines for sacrococcygeal pilonidal sinus 
wounds healing by secondary intention.  The literature and protocols that outline 
management of these wounds are limited to anecdotal evidence and case studies. 
Despite the risk of infection associated with PSWs there are few studies that have 
investigated antimicrobial prophylaxis for the management of these wounds with an 
aim to reduce wound healing times. Chaudhuri, Bekdash and Taylor (2006) 
compared prophylactic, single dose antibiotic therapy with a broad spectrum, multi 
drug regimen with 50 patients undergoing pilonidal sinus surgery and found the 
broad spectrum 5-day treatment more effective than the single dose treatment in 
preventing wound complications.  A further study by Sondenaa et al, 1995 found that 
wound healing was significantly influenced by single dose antibiotic prophylaxis.   
This randomised controlled trial (RCT) aimed to provide evidence for guiding 
treatment, and facilitating faster and more cost effective wound healing. The study 
aimed to provide a benchmark for pilonidal sinus wound healing times and guidance 
on wound management for clinicians and health care providers planning 
management strategies and supply of resources for this client group. 
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Conclusion 
Sacrococcygeal pilonidal sinus disease often requires surgical intervention which 
results in wounds healing by secondary intention. Due to the anatomical location of 
the wound there is an increased risk of overt or covert infection which can result in 
delayed healing. Current management practices for these wounds include the use of 
calcium alginate dressings with intermittent use of topical antimicrobial dressings 
when infection presents. The primary aim of this study was to determine if faster 
healing times can be achieved with the prophylactic use of a nanocrystalline silver 
alginate dressing as a topical antiseptic. The following chapters will review the 
current literature on pilonidal sinus disease, wound management, wound infection 
and use of silver as a topical antimicrobial treatment and outline the methodology, 
results, discussion and recommendations of the study. 
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Chapter 2 
Literature Review 
Introduction 
An extensive literature review was conducted using the key words: pilonidal sinus 
disease, pilonidal sinus, pilonidal abscess, pilonidal fistula, pilonidal cyst, Jeep 
disease, physiology of wound healing, wound management, wound infection, 
management of pilonidal sinus wounds, cavity wounds, calcium alginate dressings 
and silver dressings.  Written literature sources published in the last ten years were 
used for the literature review with the exception of sentinel resources. Electronic 
sources included CINAHL, Cochrane Library, InterNurse, Ovid, Proquest, PubMed 
and Science Direct. A hand search of reports, journals and relevant text books was 
also completed. The literature review was restricted to sources written in English.   
 
Pilonidal Sinus Disease 
Pilonidal sinus disease, also referred to as a pilonidal abscess, pilonidal cyst or 
pilonidal fistula, is an epithelial lined tract, cyst or abscess usually located on the 
natal cleft of the buttocks, which often contains embedded hair. The word pilonidal is 
derived from the Latin words pilus, meaning hair and nidus meaning nest (Goligher, 
1984; Miller & Harding, 2003). 
 
Pilonidal sinus disease was first described by Hodges in 1880 (Miller & Harding, 
2003). During World War II it was commonly found amongst military personnel, and 
was thought to result from driving or riding in Jeeps, trucks and tanks, hence is often 
referred to as ‘Jeep disease’ (Buie, 1944).  
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Epidemiology of Pilonidal Sinus Disease 
The incidence of pilonidal sinus disease is 26 per 100,000 and is more common in 
people of European origin than in those of Asian and African origin (Surrell, 1994). 
This is likely due to the differing characteristics of hair and hair growth patterns (Buie 
& Curtis, 1952). In 2000-2001, in the United Kingdom (UK), 11,534 hospital 
admissions for pilonidal sinus disease were reported with a mean stay of 4.3 days 
(Lanigan & Dyne, 2012). The onset of PSD is rarely reported both before puberty 
and after the age of 40 years (Miller & Harding, 2003) with the average age of 
presentation for males being 21 years and 19 years for females (Notaro, 2003; 
Ringelheim, Silverberg, & Johnson-Villanueva, 2006). It is three times more likely to 
occur in males than females (Surrell, 1994) and many individuals affected by this 
condition are hirsute. Increased incidence of this disease has been associated with 
obesity, sedentary occupation, local tissue irritation, local trauma prior to onset and a 
family history (Dwight & Maloy,1953; Holmes & Turner, 1969; Notaro, 2003). 
 
Pathophysiology of Pilonidal Sinus Disease 
The origin of sacrococcygeal pilonidal sinus disease is not fully understood, it was 
originally considered to be a congenital condition. It was postulated that individuals 
with the disease had caudal segments of the neural canal remaining, which resulted 
in multiple small cysts in contact with the skin surface. As the cysts increased in size 
they ruptured, resulting in the formation of sinus tracts (Ringelheim et al., 2006).  
 
This theory, however, came into question following World War II with the increased 
prevalence of the disease amongst soldiers. Over 78,000 soldiers received treatment 
for pilonidal sinus disease during 1941 – 1944 (Lanigan & Dyne, 2012). In addition to 
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this, pilonidal sinus disease has been reported in other parts of the body, including 
the umbilicus and inter-digital spaces of barber’s and sheep shearer’s hands 
(Ringelheim et al., 2006).  
 
Recent studies suggest that PSD is an acquired disease as a result of hair, 
hormones, friction and infection (Harris, Laforet, Sibbald, & Bishop, 2012; Miller & 
Harding, 2003). It is thought to be related to the increased production of sex 
hormones at puberty which affect the growth of the pilosebaceous glands and hair 
follicles (Harris et al., 2012; Price & Griffiths, 1985) which correlates with the age of 
onset of pilonidal sinus disease. Obstruction of hair follicles from keratin and debris 
can further perpetuate follicle enlargement with eventual rupture into the 
subcutaneous tissue causing abscess and sinus formation (Bascom, 1981). Visible 
pits in the midline of the natal cleft are associated with pilonidal sinus disease and 
microscopically have the appearance of enlarged hair follicles (Miller & Harding, 
2003). In addition to the hormonal effects, it has also been suggested that the 
enlargement of the hair follicle is due to a combination of over stretching in the 
sacrococcygeal area, due to the applied weight of the buttocks and the angle of the 
sacrococcygeal joint (Bascom, 1981).  Activities that increase the magnitude of force 
created by the overstretching in the sacrococcygeal area, such as bouncing on a 
hard seat, as in the case of "Jeep disease", or local trauma, can contribute to follicle 
rupture (Miller & Harding, 2003).  
 
Hair entry into the follicles, arising from the natal cleft in hirsute individuals or from 
head or back hair falling into the natal cleft (Bascom, 1983: Miller & Harding, 2003), 
was once thought to be the primary cause of the development of pilonidal sinus 
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disease. Hair acts as a foreign body on entering the follicles and can initiate an 
inflammatory response, subsequent infection, abscess formation or sinus disease 
(Bascom, 1983; Karydakis,1992;  McCallum et al., 2007). However, it is now thought 
that follicle enlargement precedes this, as only half of the cases are found to have 
hair in the sinus at operation (Bascom, 1981).  
 
Management of Pilonidal Sinus Disease 
Although pilonidal sinus disease has been surgically treated for over 100 years, 
management remains controversial with various different surgical procedures 
employed. However, none of these procedures satisfies all the requirements for ideal 
treatment, namely rapid healing, no need for hospital admission, minimal patient 
inconvenience and low recurrence (Mohamed et al., 2005).  
 
Sacrococcygeal PSD can be acute or chronic. In the acute phase it presents with a 
painful abscess in the natal cleft. Treatment methods for this phase include 
conservative non-surgical management with systemic antibiotics or surgical 
management with incision, drainage and curettage of the abscess plus or minus 
systemic antibiotics (Harris & Holloway, 2012). Chronic PSD presents as painful 
single or multiple discharging sinuses in the natal cleft. Surgical interventions include 
limited or wide excision of tissue affected by the pilonidal sinus. Both of these 
procedures can result in an open wound, however, they are often managed with 
primary wound closure, which may involve surgical reconstruction, depending on the 
extent of tissue excised (Facharzt, 2007; Mohamed et al., 2005).  
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Healing of open wounds occurs by secondary intention which involves the formation 
of new granulation and epithelial tissue and wound contraction. Pilonidal sinus 
wounds healing by this method of wound closure can take between 2 to 6 months 
with some anecdotal reports indicating healing times of one to two years (Harris & 
Holloway, 2012). Recurrence of PSD varies depending on the modality of treatment 
and ranges from 40 to 60% following incision and drainage of the abscess, 37% for 
incision and primary closure and 7.3 to 9.6% for more complex surgical 
reconstructive procedures such as rotational flaps and Z-plasty (Banerjee, 1999; 
Bascom, 1981; Torkington, 2004).  
 
A systemic review conducted by The Cochrane Collaboration (2007) assessed the 
effects of open versus closed surgical treatment of pilonidal sinus disease in relation 
to time to heal, wound infection and rate of recurrence of pilonidal sinus. A total of 18 
studies were included in the review. Seven studies reported on time to healing and 
compared open versus closed methods of treatment. Median time to wound healing 
amongst all studies ranged from 10.3 to 70 days, with all seven trials reporting 
quicker time to wound healing after primary closure (Gencosmanoglu, 2005; 
Hameed, 2001; Khawaja, Bryan, & Weaver, 1992 ; Rao, Zawislak, & Gilliland, 2001; 
Sondenaa et al., 1992).  
 
The rate of surgical site infection (SSI) following surgical intervention for PSD was 
relatively low except for two studies where the infection rate following open surgical 
procedures was 22% and 14% respectively (Fazeli, Adel, & Abaschi, 2006; 
Sondenaa et al., 1992). However, no difference in post-operative infection rates was 
reported in the pooled data of all the studies (McCallum et al., 2007).  
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Recurrence rates were reported in 11 studies, and although relatively low overall, 
analysis of pooled data suggested a 58% lower risk of recurrence after surgical 
treatment and wound healing by secondary intention as compared to surgical 
treatment and primary wound closure (al-Hassan, Francis, & Neglen, 1990; Fazeli et 
al., 2006; Fuzun et al., 1994; Gencosmanoglu, 2005; Hameed, 2001; Khawaja et al., 
1992 ; Kronborg, Christensen, & Zimmermann-Nielsen, 1985; Miocinovic, Horzic, & 
Bunoza, 1999; Mohamed et al., 2005; Sondenaa et al., 1992; Testini et al., 2001).  
 
The impact of PSD on a person can have a negative effect on their quality of life due 
to pain, wounding and recurrent infection. Additionally, it can disrupt many aspects of 
their life including work, education, socialisation and intimacy (Harris & Holloway, 
2012). A retrospective study by Haitham et al. (2007) found that patients with SSI 
had more lost time from work and longer times to wound healing. Lost time from 
work has the potential to lead to financial constraints and stress, which could further 
impact on wound healing. 
 
Physiology of Wound Healing 
Acute wounds are defined as ''a disruption of the integrity of the skin and underlying 
tissues that progress through the healing process in a timely and uncomplicated 
manner'',(Bates-Jensen & Woolfolk, 2007, p.322). Typically, surgical wounds healing 
by primary or secondary intention are considered to be acute, unless wound healing 
is complicated by intrinsic or extrinsic factors such as age, comorbid conditions or 
infection (Carville, 2012).  
  
12 
 
Regardless of the aetiology of the wound, the repair processes are similar. A 
coordinated physiological response occurs to initiate haemostasis and stimulate the 
inflammation, proliferation/reconstruction and maturation or remodelling phases of 
wound healing (Young & McNaught, 2011). Each of the phases in wound healing 
can overlap, however they remain distinct in relation to time after injury (Holloway, 
Harding, Stechmiller, & Schultz, 2012).  
 
Haemostasis occurs at the time of tissue injury with constriction of capillaries to stem 
bleeding (Carville, 2012; Holloway et al., 2012). The reduced blood flow and tissue 
hypoxia, promotes the release of vasoactive metabolites to cause a reflex 
vasodilatation. Simultaneously, histamine is released from the mast cells which 
further enhances vasodilatation and increases vascular permeability (Young & 
McNaught, 2011). The increase blood flow results in the typical signs of inflammation 
that occur soon after injury, namely erythema, swelling, heat and discomfort at the 
site of the injury (Carville, 2012). Formation of a blood clot also aids in haemostasis 
and occurs through three mechanisms. The intrinsic pathway, which results in the 
formation of a fibrin plug, the extrinsic pathway, which results in thrombin activation 
and platelet activation which not only assists with clot formation but also produces 
growth factors and cytokines which aid in regulating the healing cascade (Young & 
McNaught, 2012). 
 
The inflammatory phase of healing follows haemostasis with a key aim to prevent 
infection, it lasts from time to injury to day 4 (Carville, 2012). Through a process of 
chemotaxis, neutrophils, macrophages and T-lymphocytes infiltrate the wound to 
destroy bacteria and wound debris (Carville, 2012; Young & McNaught, 2012). 
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Neutrophils produce protein digesting enzymes, such as matrix metalloproteinases 
and serine proteases to facilitate their migration into the extra-cellular matrix (ECM) 
and kill bacteria by the process of phagocytosis (Carville, 2012; Holloway et al., 
2012).  Macrophages phagocytose devitalised tissue and bacteria in addition to 
releasing a variety of growth factors and cytokines to stimulate angiogenesis and the 
recruitment of fibroblast for the production of collagen (Schultz, Ladwig & Wysocki, 
2005). 
 
The reconstructive phase of wound healing is characterised by the development of 
new granulation and epithelial tissue, angiogenesis and wound contraction, it occurs 
from day 2 to day 24 (Carville, 2012). The macrophages bind to the ECM and 
continue to release growth factors to stimulate angiogenesis, collagen synthesis and 
fibroblast proliferation (Schultz et al., 2005). The provisional ECM is denatured and 
replaced with granulation tissue which is comprised of collagen fibres, 
glycosaminoglycans, elastin and capillary loops (Doughty & Sparks-Defriese 2007). 
Myofibroblasts have a contractile ability and contract to draw the wound edges 
together to reduce the wound surface area and the amount of tissue replacement 
required. Epithelial cells migrate over the granulation tissue from surrounding wound 
edges or from hair follicles sweat and sebaceous glands in the wound (Carville, 
2012).    
 
The maturation or remodelling phase of wound healing involves the reorganisation of 
the tissues to minimise scarring and improve tensile strength of the wound and 
occurs from day 24 to 1 year, following complete re-epithelialisation of the wound 
(Carville, 2012). It is anticipated, therefore, that acute wounds following a normal 
14 
 
healing process would be fully re-epithelialised within 24 days of injury (Holloway et 
al., 2012). 
 
Principles of Wound Management  
When a person has a wound it is important that the wound is managed appropriately 
to optimise time to healing and minimise the risk of complications. Inappropriate 
wound management can result in delayed healing, increased health care costs, 
prolonged patient suffering and lost time from work. Optimal wound care involves 
addressing every aspect of the patient and their wound in order to maximise their 
quality of life whilst the wound is present (Wounds UK, 2008). 
 
The Australian Wound Management Association (2010) recommend a 
comprehensive assessment of the person with a wound that reflects the health, 
cultural and environmental factors that have the potential to impact on wound 
healing. Initial and ongoing wound assessments that result in documented evidence 
of the wound provide objective data to enable the clinician to monitor progress of the 
wound, identify complications of wound healing and implement appropriate 
strategies to facilitate healing. Acute wounds usually proceed through the phases of 
wound healing in a timely fashion, resulting in frequent changes to wound 
dimensions and clinical appearance. This necessitates the need for regular 
documented assessments of the wound and the person to accurately capture the 
healing continuum.   
 
Assessment of a wound and prediction for healing is a complex process. Repeated 
measurement of wound dimensions are important components of this process to 
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provide objective parameters for baseline wound size and ongoing monitoring of 
healing. Additionally, determining the percentage of reduction of the wound area 
over time is useful to monitor response to treatment (Flanagan, 2003). Various 
methods of wound measurements have been utilised in clinical practice and 
research to ascertain wound surface area including, diameter product measurements 
(multiplication of wound dimensions length, width and depth), contact tracing of the 
wound margin, square counting (tracing of wound on a grid) and planimetry (surface 
area of tracing or digital wound image). Diameter product measurements can be 
limited, especially when calculating wound surface area as they do not provide a 
precise overall wound size, especially for irregular shaped wounds which may be 
over or under estimated (Majeske, 1992). In addition, with serial measures, although 
the wound dimensions may change, once multiplied the surface area could remain 
static (Flanagan, 2003). Identifying wound surface area by contact tracing of the 
wound perimeter or from a 2 dimensional digital image can be more accurate 
however, factors such as patient positioning, tissue distortion and body curvature 
can decrease accuracy (Plassmann, 1995). Rogers, Bevilacqua, Armstrong, and 
Andros (2010) compared 3 dimensional digital planimetry, using the 
SilhouetteMobile® camera to standard ruler measurements and found this method to 
be more accurate, with ruler measurements overestimating the wound size by 
approximately 40%. However, regardless of modern technology, multiple factors 
including anatomical location of the wound can still impact on accuracy and although 
this can be improved with consistency in methodology and patient positioning 
(Baranoski, Ayello, & Langemo, 2012), more research is required to validate this 
method of wound measurement.   
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Diameter product measurements are commonly used in clinical practice as this 
method is inexpensive and readily available (Baranoski et al., 2012). Although it is 
usual to use 3 dimensional linear measurements, that is length, width and depth, 
only 2 dimensional linear measurements were used in this study due to the 
anatomical positioning of wounds in the sacrococcygeal area preventing accurate 
assessment of width, hence it was not measured. Two dimensional linear 
measurements of multiplication of length and depth were used to assess baseline 
wound size and monitor wound progression.  Marks, Hughes, Harding, Campbell, 
and Ribeiro (1983), explored the relationship between the size and healing of 
surgical wounds and identified a correlation of 0.89 for pilonidal sinus wounds using 
the greatest of the wound dimensions. It was determined that any one of the wound 
measurements i.e. length, width or depth could be used to predict healing.  
 
Factors Affecting Wound Healing 
Delays in acute wound healing can occur from several factors including wound 
infection (Bates-Jensen & Woolfolk, 2007; Carville, 2012). Surgical site infections 
have been reported to be between 2-13% in Australia, depending on the surgical 
procedure undertaken (Department of Health and Aging, 2001), with most of the 
cases appearing after discharge from hospital (Nicholas et al., 2006). Wound 
infection delays healing by prolonging the inflammatory phase and disrupting the 
proliferative phase of wound healing, thereby reducing the tensile strength of the 
new wound tissue (Gardner & Frantz, 2012).  
 
Surgically created wounds are contaminated by bacteria soon after wounding and 
often the wound provides an environment that is conducive to the growth of micro-
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organisms. The potential for bacteria to produce harmful effects to the wound and 
the patient is influenced by the number and type of bacteria and the ability of the 
patient’s immune system to resist the bacteria (Healy & Freedman, 2006).  Higher 
numbers of bacteria in the wound environment have a greater ability to overcome the 
patient’s immune resistance and hence cause infection. In addition, some bacteria 
are more virulent than others and therefore have a greater capacity to produce 
disease (Principles of Best Practice, 2008). Wound infection is more likely to occur in 
patients with contaminated or dirty wounds (Briggs, 1997) or following surgery 
involving abscesses where significant numbers of bacteria may already be present 
(Wilson, 1995), which is often the case with pilonidal sinus wounds.   
 
In acute wounds, the signs and symptoms of wound infection are typically heat, new 
or increasing pain, oedema, local warmth, purulent exudate and erythema (Cutting & 
Harding, 1994). However, covert infection or critical colonisation may not be so 
obvious and may have more subtle signs and symptoms such as changes in 
granulation tissue, increased exudate and static or delayed healing (Principles of 
Best Practice, 2008).  
 
Other common factors that impair wound healing in the younger person include 
malnutrition, reduced tissue oxygenation, non-viable tissue, excessive pressure, 
shear or friction, psychophysiological stress, co-morbid conditions and adverse 
effects of treatment (Stotts, Wipke-Tevis, & Wopf, 2007).  
 
Wound healing is dependent on an adequate nutritional state and can be impaired 
by either inadequate intake of nutrients or pre-existing malnutrition (Stotts et al., 
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2007).  Nutrients that are essential for healthy skin and repair following injury include 
protein, amino acids, carbohydrates, lipids, vitamins, minerals and water (Lansdown, 
2004 ). Protein requirements increase during wound healing and when intake is not 
sufficient it can result in decreased fibroblast proliferation, angiogenesis, collagen 
synthesis and remodelling (Stotts et al., 2007). As with protein, there is also an 
increase requirement for carbohydrates due to the increased energy requirements to 
meet the hyper-metabolic response that occurs with wounding. When there is 
insufficient carbohydrate intake, body protein is utilised for energy. Hence, protein is 
diverted to provide the required glucose for cellular maintenance rather than for 
tissue repair (Ord, 2007 ; Stotts et al., 2007). Insufficient intake of lipids can reduce 
the intake of fat soluble vitamins A, D, E and K. Deficiency in vitamin A can impair 
healing by affecting the inflammatory response and decreased collagen formation 
can result from deficiencies in vitamin B and C, zinc, iron, copper and magnesium 
(Ord, 2007 ; Stotts et al., 2007).  
 
Young people may experience a change in their nutritional intake as their body 
develops and they become more independent with food choices, which has the 
potential to put them at risk of nutritional deficits. There is an abundance of 
guidelines available on the nutritional requirements for adolescents, however, there 
is limited evidence available on their nutritional status.  Song, Schuette, Huang, and 
Hoer-r (1996) studied a 24 hour dietery intake of 2,489 young adults and found that 
although their mean intake of the five major food groups was above the 
recommended amount, at least 89% of the young adults consumed less than the 
recommended number of servings from more than one food group including grains, 
vegetables, fruit, dairy and meat. A survey of adolescent nutritional intake by the 
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Australian Institute of Health and Welfare (2007) found that 34% of males and 53% 
of females aged 18 years were consuming less that the estimated average 
requirements of daily energy intake and only 26% of adolescents aged between 15 
and 19 years consumed at least 3 serves of fruit per day.  
 
It is well documented that smoking has the potential to impair wound healing by 
several mechanisms. The components of tobacco namely nicotine, carbon monoxide 
and hydrogen cyanide are thought to be responsible for the harmful effects. Nicotine 
is a potent vasoconstrictor and increases platelet aggregation resulting in an 
increased risk of micro-vascular thrombosis and ischaemia (Rayner, 2006). Carbon 
monoxide reduces the oxygen carrying capacity of haemoglobin and lowers oxygen 
saturation, whereas, hydrogen cyanide inhibits the cellular transport of oxygen. 
Hence, a major adverse effect of smoking is wound hypoxia (Rayner, 2006; Stotts et 
al., 2007). It is postulated that smoking a single cigarette creates a vasoconstrictive 
effect that can last up to 90 minutes and smoking a packet of cigarettes a day results 
in tissue hypoxia for 24 hours (Smith & Smith, 2012).  
 
Various lifestyle and occupational factors have been suggested as predisposing 
factors for pilonidal sinus disease including sedentary lifestyle, local irritation and 
trauma to the sacrococcygeal area prior to onset (Dwight & Maloy, 1953; Holmes & 
Turner, 1969; Notaro, 2003). The significant increase in this condition amongst 
soldiers in World War II was thought to be due to the repeated bouncing and jolting 
from riding in military vehicles (Jeeps) resulting in irritation and trauma to the 
sacrococcygeal area (Buie, 1944). However, pressure, shearing and friction forces 
can be potential problems not only from physical activity but also from sedentary 
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activities such as prolonged sitting. Additionally, smoking and obesity have been 
reported as independent risk factors for infection specifically relating to pilonidal 
sinus disease (Haitham et al., 2007). 
 
Management of Pilonidal Sinus Wounds 
Controversies exist in relation to surgical procedures to treat pilonidal sinus disease 
and the resultant post-operative management. However, in relation to the literature, 
there is significantly less available relating to the post-operative management of 
these wounds as compared to the surgical procedures. It has been suggested that 
the shape of the post-operative wound base may have an effect on healing of PSWs 
and disease recurrence. Pilonidal abscesses treated by surgical incision and 
drainage often result in a narrow wound base where excision of the pilonidal sinus is 
likely to result in a wound with a wide base due to tissue resection. No studies have 
compared healing based on the shape of the post-operative wound. Pilonidal sinus 
wounds healing by secondary intention result in a cavity and thus have a tendency to 
heal from the base and sides (Marks et al.,1983) and lightly packing such wounds 
with a suitable wound dressing product will facilitate this healing, preventing early 
closure and reducing the likelihood of abscess formation (Carville, 2012) or in the 
case of PSD, recurrence. 
 
Although effective wound management will promote wound healing and minimise the 
risk of infection, there is no consensus as to which wound dressing is the most 
appropriate for PSWs. Moist wound healing is widely accepted by most clinicians as 
best practice to support the physiological process of wound repair. Epithelial cells 
require a moist environment to enable their migration across the wound bed to 
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resurface the wound area (Baronoski, Ayello, McIntosh, Montoya, & Scarborough, 
2012).  Consequently, dressings that are used on PSWs need to be moisture 
retentive or moisture balanced to optimise wound healing. Generally, the dressing, 
needs to promote client comfort, be flexible to match the contours of the natal cleft 
and wound, retain moisture at the wound interface and be cost effective (Carville, 
2012; Harris & Holloway, 2012).  
 
Traditionally, in Australia, PSWs have been managed with saline soaked gauze 
dressings and although more contemporary dressings are now being used; this 
suboptimal practice continues to be employed in some sectors. Saline soaked gauze 
dressings have a tendency to dry the wound bed and subsequently increase the 
client’s level of pain especially at dressing changes (Harris & Holloway, 2012).  
Stewart et al., (2004) reported low pain scores for patients with PSWs, however, a 
further study by Stewart, Donoghue, and Mitten-Lewis (2008) found that pilonidal 
sinus wounds were more painful at dressing changes than at rest or during activity, 
with higher pain levels being reported by participants using saline soaked gauze. 
Price et al., (1994), studied quality of life on 80 individuals with surgical wounds 
(78% had a PSW) and identified that pain negatively impacted on the person’s ability 
to sleep and diminished their appetite, at a time when they have increased nutritional 
requirements. Furthermore, pain can activate a stress response, which has the 
potential to impede normal wound healing (Woo, Harding, Price, & Sibbald, 2008).  
In addition to this, saline soaked gauze dressings are costly due to the requirement 
for frequent dressing changes in an attempt to avoid the dressing drying out 
(Carville, 2012; Ryan, 2008). Frequent dressing changes, not only result in increased 
wound product use but also increased nursing time. 
22 
 
 
A study conducted by Viciano et al. (2000), compared two different hydrocolloid 
dressings with a gauze dressing for 38 patients with pilonidal sinus wounds. The 
study reported median healing time of 68 days for the gauze dressing and 65 days 
for the combined hydrocolloid dressings, concluding that the hydrocolloid dressing 
did not reduce healing time. Stewart et al. (2008) studied 55 patients who had 
undergone surgical excision of pilonidal sinus for 12 weeks. The participants used a 
variety of wound dressings including calcium alginate, hydrofibre, saline gauze, 
petroleum gauze, silver foam and povidine iodine packs. Although, 60% of 
participant’s wounds were healed by 12 weeks, the study found no correlation 
between dressing type and wound healing.  
 
Calcium Alginate Dressings 
Calcium alginates have been used for clinical purposes since the 1940s (Thomas, 
1992). Calcium alginate wound dressings are derived from calcium salt of alginic 
acid which is obtained from certain species of brown seaweed (Thomas, 1992). They 
are designed as primary wound dressings and when in contact with serum, wound 
exudate, or solutions containing sodium ions, the insoluble calcium alginate is 
converted to the soluble sodium salt, and a soft, hydrophilic, gas permeable gel is 
produced. The gelled product conforms to the contours of the wound and provides a 
micro-environment that facilitates wound healing (Thomas, 2006). 
 
Calcium alginate rope dressings are a suitable choice for packing cavity wounds and 
are therefore a suitable choice for PSWs. The gel formed by calcium alginate 
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dressings when in contact with wound fluid provides a moist environment at the 
wound interface.  
 
Calcium alginates have been compared to the use of saline-soaked gauze dressings 
for packing abscess cavities following surgical incision and drainage and were found 
to perform significantly better in relation to ease of removal (p < 0.01) and reduction 
in pain on removal of dressing (p < 0.01), (Dawson, Armstrong, Fulford, Faruqi, & 
Galland, 1992). In addition, calcium alginates have been shown to have haemostatic 
properties. A study by Groves and Lawrence (1986), demonstrated that alginates 
were able to produce significant haemostasis within 5 minutes of surgery and 
absorbed nearly three times as much citrated blood as surgical gauze when used on 
skin graft donor sites. The evidence available regarding calcium alginate dressings in 
relation to haemostasis and reduced level of pain on dressing removal were 
considerations for the researcher in selecting this product for the study.  
 
Additionally, achieving haemostasis post wounding is of primary importance. The 
calcium alginate selected for use in this study was done so to minimise confounding 
factors, it is manufactured by the same company as the nanocrystalline silver 
alginate dressing and is therefore the same except for the silver component.  
 
Silver Dressings 
Wound dressings containing antiseptic properties, such as silver, are used to 
manage wounds with covert or overt infection. The use of silver as an antimicrobial 
agent dates back to ancient Greek and Roman times when silver coins were used to 
sterilise drinking water (White, 2001). It has been used as an antibacterial for 
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medical purposes since the 18th century (Graham, 2005) and by the early 20th 
century silver was used to treat bacterial infections in wounds (White, 2001).   The 
use of silver diminished following the discovery of antibiotics in the 1930’s, however 
the emergence of antibiotic resistant strains of bacteria such as methicillin resistant 
Staphylococcus aureus (MRSA) and vancomycin resistant enterococcus (VRE) has 
renewed the interest in topical antimicrobial agents including silver (DTB., 2010). 
 
Ionic silver is a potent antimicrobial and is effective at low concentrations against a 
broad range of micro-organisms including Gram-positive and Gram-negative 
bacteria, MRSA, VRE, fungi, protozoa and viruses (DTB., 2010; Herman, 2006; 
Russell & Hugo, 1994). Antiseptic agents have a reduced propensity to induce 
bacterial resistance than antibiotics, therefore, they are useful to treat localised skin 
and wound infections (Percival et al., 2005).  
 
The exact mechanism of silver’s antimicrobial effect is not fully understood, however 
it is thought to bind to tissue proteins causing structural changes in the bacterial cell 
walls and intracellular and nuclear cell membranes resulting in cell death (Lansdown, 
2002; Percival et al., 2005). In addition, silver binds to and denatures bacterial 
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) preventing replication and 
reducing microbial metabolism and growth (DTB., 2010; Lansdown, 2002; Percival et 
al., 2005). Silver’s broad spectrum antimicrobial activity in addition to its relatively 
safe nature have contributed to its increased use in wound management, particularly 
as bacteria found in wounds are usually of mixed species, requiring broad spectrum 
treatment (Percival et al., 2005). 
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The increased demand for antimicrobial dressings, has seen the number and variety 
of silver dressings on the market grow, with silver being added to contemporary 
dressings which include calcium alginate, activated charcoal, semi-permeable films, 
hydrocolloids and polyurethane foams (Cutting, White, & Hoekstra, 2009). The 
majority of studies relating to the antimicrobial activity of silver dressings have 
investigated the efficacy of nanocrystalline silver, as it is able to maintain a higher 
level of active silver cation (5mg/l – 40mg/l) than other silver dressings (Leaper, 
2011). 
 
Nanocrystalline silver wound dressings have been found to rapidly deliver silver and 
in higher amounts than other types of silver dressings due to the greater surface 
area created by the nanoparticles. This results in a significantly faster reduction of 
bacteria than experienced with other forms of silver dressings (Brett, 2006; 
Wilkinson, White, & Chipman, 2011), as the level of silver has been found to be 
directly proportional to the rate of kill of the micro-organisms (Ovington, 2001). 
Nanocrystalline silver is present in the ActicoatTM range of wound care dressings 
manufactured by Smith & Nephew. A study by Thomas and McCubbin (2003), 
compared the antibacterial effect of four different types of silver dressings, and 
concluded that ActicoatTM had marked antimicrobial activity with a rapid onset of 
action as compared to the other dressings.  
 
In addition to the antimicrobial effects of silver, scientific studies have demonstrated 
an anti-inflammatory and pro-healing effect of nanocrystalline silver, which is 
independent of the antimicrobial effect (Bhol & Schechter, 2004; Nadworny, Landry, 
Wang, Tredget, & Burrell, 2010; Nadworny, Wang, Tredget, & Burrell, 2008). 
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Histological data suggested nanocrystalline silver promoted healing by enhancing 
rates of tissue repair including formation of new granulation and epithelial tissue 
(Nadworny et al., 2010).  
 
The increased use of silver in wound management has led to an increased concern 
regarding the potential for resistant strains of bacteria. However, because antiseptics 
have multiple mechanisms of action, bacterial resistance is less likely than that 
caused by antibiotics, which have a single targeted effect (Leaper, 2011). To date, 
there have been no reports that have demonstrated a link with bacterial resistance to 
contemporary silver dressings (Leaper, 2011). It is postulated that the risk of 
resistance from silver dressings can be minimised by utilising dressings with high 
levels of silver that facilitate a rapid antibacterial effect and thus reduces the 
possibility of bacterial mutation and resistance (Ovington, 1999, 2001).  
 
Some authors express concerns about the systemic absorption of silver and the 
potential for hypersensitivity and toxicity which stems from the known cytotoxic 
effects of nitrate ion, a strong oxidising agent, found in silver nitrate (European 
Wound Management Association, 2006). Early use of silver formulations, such as 
solutions and creams, for treating open wounds has been associated with several 
side effects, including cytotoxicity, staining of skin and fabric, methaemoglobinaemia, 
electrolyte disturbance and retardation of wound healing (European Wound 
Management Association, 2006). The cytotoxicity of silver sulfadiazine is associated 
with release of the sulphonamide rather than silver, and has been associated with 
severe blood and skin disorders including burning, itching and rashes. Leucopenia 
and argyria a skin decolourisation resulting from elemental silver deposition, have 
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also been recognised with the use of silver (Mehta, 2005). Silver impregnated 
dressings that facilitate controlled release and deposition of silver, ensure 
antimicrobial activity whilst reducing the potential risk of toxicity and other side 
effects (Walker, Cochrane, & Bowler, 2006). A study by Honari, Gibran, Engrav, 
Carlson, and Heimbach (2001), compared the effects of silver sulphadiazine (SSD) 
to nanocrystalline silver on patients with MRSA over 8 months and found 
nanocrystalline silver had no negative effects on healing rates. 
 
Despite the scientific evidence available regarding the antimicrobial effects of silver, 
there is a lack of good-quality clinical trials to support the extensive use of silver 
impregnated wound care products (European Wound Management Association, 
2006).  Considering, the British National Health Service reported expenditure of £25 
million in 2006 on silver impregnated wound care products, further clinical trials are 
required (DTB. 2010). 
 
An international consensus document on the use of silver in wound care 
recommends that antimicrobial dressings, including silver are used initially for 2 
weeks to treat overt or covert wound infection with evaluation of the patient, wound 
and management following this time to evaluate effectiveness (Wounds International, 
2012). In addition, it supports the use of silver dressings for prophylactic use as a 
barrier to microorganisms in wounds at high risk of infection such as wounds near 
the anus (Vowden, Vowden, & Carville, 2011; Wounds International, 2012). 
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Conclusion 
Pilonidal sinus disease has been surgically treated for more than a hundred years, 
despite this, there is little guidance available for the management of PSWs. Due to 
the anatomical location and pathophysiology of this condition PSWs are at increased 
risk of infection which can delay wound healing. Calcium alginate wound dressings 
are often used for PSWs healing by secondary intention, however intermittent 
treatment with a topical antimicrobial dressing is often required to maintain the 
wounds bacterial balance. Silver is a broad spectrum topical antimicrobial agent that 
is widely used in the management of wound infection and it is available in a variety of 
contemporary dressing products. Nanocrystalline silver delivers a high level of silver 
to achieve a rapid and sustained bactericidal effect and is reported to be relatively 
safe when used to manage wound infections.     
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Chapter 3 
Methodology 
Study Design 
A randomised controlled trial (RCT) was conducted to investigate the prophylactic 
effect of nanocrystalline silver alginate dressings as compared to calcium alginate 
dressings in pilonidal sinus wounds healing by secondary intention, following surgical 
excision or incision.   
 
Study Population 
Clients referred to Silver Chain metropolitan nursing services with a sacrococcygeal 
wound healing by secondary intention, following surgical excision or incision of a 
pilonidal sinus and who met the inclusion criteria were invited to participate. The 
client’s treating surgeon was informed in writing of each client's consent to 
participate. In addition, study information was forwarded to surgical departments of 
public and private hospitals within Western Australia’s metropolitan area to inform 
them of the study and to invite them to refer their clients for recruitment. 
 
Participants were randomly assigned to either receive a nanocrystalline silver 
alginate dressing (experimental group) or a calcium alginate dressing (control group) 
as treatment for their pilonidal sinus wounds.  
 
The required sample size for the study was calculated based on a mean healing rate 
of 46 days (SD 10 days) and an effect size of a 6 day reduction in the time taken to 
heal in the intervention group (46 days versus 40 days) with a significance level of 
0.05 and power set to 80%. The above calculation resulted in the need to recruit 30 
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participants per group. However, as potential crossover of clients from the calcium 
alginate group to the nanocrystalline alginate group was a possibility if a client in the 
calcium alginate group should have developed signs and symptoms of infection, a 
maximum of 44 clients per group was determined necessary.  
 
Inclusion Criteria 
The study inclusion criteria were: 
• Aged 16 – 40 years,  
• Day 2 - 7 post-operative (on referral to Silver Chain),  
• Able to provide consent (parental consent was obtained for clients under 
18years of age). 
 
Exclusion Criteria  
The study exclusion criteria were: 
• Under 16 years of age, 
• Known allergy to silver or calcium alginate dressing products, 
• Pregnant or lactating women, 
• Failure to provide consent or obtain parental consent if under 18 years, 
• Inability to have wound dressed on daily basis for duration of the study period 
or until wound healing was achieved. 
 
Recruitment 
Due to the geographical spread of Silver Chain's community clients, it was not 
feasible or practical for the principal nurse researcher (the student, Margaret 
Edmondson) to recruit and collect data for all participants. Thus, it was decided to 
appoint study research nurses at each service centre to facilitate and supervise 
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recruitment of participants and data collection. Nurses described as study research 
nurses were registered nurses employed by Silver Chain in the metropolitan area, 
who had advanced wound care skills and previous experience in data collection for 
research purposes. The study research nurses were educated by the principle nurse 
researcher to recruit study participants, collect study data and perform the study 
wound care protocols. The scheduled visiting nurses were registered or enrolled 
nurses employed by Silver Chain in the metropolitan area, who delivered client care 
to study participants on the days data collection was not required. The scheduled 
visiting nurses were educated to identify potential study participants and perform the 
study wound care protocols.  
 
All clients referred to Silver Chain who met the study criteria and who did not meet 
any of the exclusion criteria were invited to participate in the study. If the client (or 
their authorised representative) expressed interest in participating in the study, they 
were given the Study Information Sheet (Appendix l) and Consent Form (Appendix ll) 
and informed that a research nurse would contact them. The research nurse then 
contacted the client within 24 hours by telephone and enquired whether they, or their 
representative, had read the Study Information Sheet and if they had any questions. 
The research nurse then made an appointment with the client to attend the next 
scheduled visit for wound care and to enrol the client in the study. At that visit, the 
client was given the opportunity to ask any further questions and they were asked to 
sign the Consent Form if they wished to participate. 
 
If consent was not obtained, the research nurse provided usual care for the client in 
accordance with the current wound care plan and Silver Chain services were 
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continued as before. When an individual had given consent to participate in the 
study, the research nurse opened a randomly selected envelope which informed the 
nurse of the randomised selected dressing to be used. The nurse then implemented 
the care defined by the study protocol for the dressing group the individual was 
randomised to. 
 
Randomisation 
The allocation of study numbers to intervention and control groups was done using 
the Excel Microsoft software random number function. Envelopes were numbered 
sequentially and a slip of paper indicating group allocation was sealed inside. These 
study envelopes were prepared centrally by the principle research nurse and 
randomly divided and distributed to the service centres where they were accessible 
to the research nurse(s) working out of that centre. The research nurses used the 
envelopes from the service centres sequentially when they recruited clients. If the 
client was not recruited to the study, the unused envelope was returned to the 
service centre.  
 
Data Collection Procedure 
Data collection involved the completion of an Initial Data Collection Form (Appendix 
lll) and subsequent Weekly Data Collection Forms (Appendix lV); wound 
measurement, photograph and swabs. Demographic and other routinely collected 
service data was extracted from Silver Chain's client database, ComCare.  
The data collection protocol included:   
• Demographic data and clinical data relating to the client, which were collected 
as a normal part of care in Silver Chain, were sourced from ComCare (Silver 
Chain’s client database). 
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• Completion of the Initial Data Collection Form at recruitment,  
• Completion of Weekly Data Collection Form at weekly intervals for a maximum 
period of 8 weeks, 
• Digital images of the wound at recruitment and each week for a maximum 
period of 8 weeks as per Wound Photograph Protocol for Pilonidal Sinus Study 
(Appendix V), to confirm the anatomical location of the wound and compare the 
clinical appearance of the wound tissue with the documented wound 
assessment. 
• Wound swabs at recruitment and weeks 4 and 8, for microscopic culture and 
sensitivity analysis. Although, the precise technique for wound swab collection 
has not been identified or validated, the Z-technique of moving the swab across 
the wound surface in a zig-zag pattern whilst rotating and applying pressure 
(Cooper, 2010), was utilised for this study to optimise collection of organisms 
within the wound. A protocol for wound swab collection (Appendix Vl) was 
provided to all staff involved in data collection to facilitate consistency of swab 
collection.  
• Additional swabs were taken if wound infection was suspected, to confirm 
diagnosis, isolate pathogens and determine susceptibility, should systemic 
antibiotic therapy be required. 
• The length and central depth (perpendicular to the skin surface) of the wound 
were measured at recruitment and at weekly intervals using the Visitrak™ 
calibrated sterile measurement probe. Wounds in the sacrococcygeal area, due 
to the tissue curvature in this area do not necessarily demonstrate a width in 
the normal anatomical position. Hence, width was not used as a measure 
towards healing as it was unable to be measured accurately. Other researchers 
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(Marks et al.,1983) have used two-dimensional wound measures as predictors 
to wound healing in similar circumstances.   
 
To assess for factors other than wound infection that may delay wound healing the 
Charlson Comorbidity Index (CCI) was used. Although the CCI is used to predict 
mortality it has been used in other wound related studies to identify co-morbid 
conditions that have the potential to impair wound healing (Miller et al., 2010). In 
addition to this, malnutrition was further assessed using the Home and Community 
Care Nutritional Screening and Monitoring Tool (HACC-NSMT). There is limited 
availability of validated tools to adequately assess nutrition and although the HACC-
NSMT tool is designed to assess for changes in weight, appetite and barriers to 
adequate nutrition rather than the composition of the food a person is eating, it 
provided a degree of assessment for potential nutritional deficits. 
 
Study Intervention 
Study participants were randomly assigned to receive either a nanocrystalline silver 
alginate dressing (Acticoat AbsorbentTM) or a calcium alginate dressing (AlgisiteTM). 
Both of these products are manufactured by Smith and Nephew, hence the products 
are the same apart from the nanocrystalline silver component of the ActicoatTM and 
were selected to minimise any confounding factors. The manufacturers of the 
products made no financial contribution to the study; products were purchased by 
the organization for client use. Wound treatments in both groups involved daily 
wound dressings for 8 weeks or earlier if wound healing had occurred.  Healing was 
defined as 100% epithelialisation of the wound bed.  
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The care plan for the allocated treatment was written in the client’s home record at 
the study recruitment visit. All Silver Chain metropolitan domiciliary nurses received 
education in regard to the study protocol and the randomised treatment regimens 
prior to commencement of the study. The designated research nurses provided the 
treatment for the client at recruitment and at weekly data collection visits; whilst the 
client’s scheduled visiting nurse provided the treatment on intervening visits. Thus 
neither the research nurse nor the visiting nurse was blind to group assignment. 
Wound management involved the client showering, prior to dressing changes. If the 
client was receiving clinic based care, a temporary sterile dressing pad was provided 
to the client to apply after showering at home to protect the wound during transit to 
the clinic. Wounds were cleansed with sterile water prior to the application of the 
randomized dressing and an absorbent pad was applied as a secondary dressing to 
absorb wound exudate, which was secured with dressing tape. 
 
Protocol When Signs of Infection Identified 
If clients developed signs and symptoms of local wound infection, as determined by 
the presence of increased, malodorous or purulent exudate, friable or bridging of 
granulation tissue and increased pain (Principles of Best Practice, 2008), additional 
data was collected including the completion of a Weekly Data Collection Form 
(Appendix lV), wound image and wound swab. Wound swabs for microscopic culture 
and sensitivity were collected from participants to determine semi–quantitative 
bacteriology. The client's medical practitioner was notified and a copy of the wound 
swab result was forwarded to him/her. 
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Clients in the calcium alginate group who displayed signs or symptoms of critical 
colonisation or infection had their dressing regime changed to the nanocrystalline 
silver alginate dressing and the care plan was changed accordingly. Clients in the 
nanocrystalline silver alginate group displaying signs or symptoms of critical 
colonisation or infection continued with the nanocrystalline dressing. Clients in both 
groups who developed signs and symptoms of localised (erythema, increased skin 
temperature, purulent exudate) or systemic infection (signs of local infection plus 
pyrexia and/or general malaise, rigours) were referred to their treating medical 
practitioner for consideration systemic antibiotic treatment.  
 
When the signs and symptoms of local or systemic infection were no longer present, 
and any prescribed treatment completed, further data was collected, which included 
completion of Weekly Data Collection Form, wound image and collection of wound 
swab. Clients originally in the calcium alginate group were recommenced with the 
calcium alginate dressing and the care plan was updated accordingly. Clients in the 
nanocrystalline silver alginate group continued with the nanocrystalline silver alginate 
dressings. Clients that had recurrent episodes of local or systemic infection during 
the 8 week study period had the above procedure repeated.  
 
On completion of the study period, ongoing treatment for wounds that had not healed 
was determined by the visiting nurse based on the assessment outcome of the 
wound at the final study data collection point (week 8).  
The anti-inflammatory property of the nanocrystalline silver alginate dressing was a 
consideration in the timeframe for recruitment to this study due to the potential of the 
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dressing to interfere with the normal inflammatory phase of wound healing which 
occurs from days 0 to 4 of wounding.  
 
Data Analysis 
For data analysis purposes the dataset was split into a ‘participant’ file of 48 records, 
and a ‘wound’ file of 576 records. Essentially, the participant file held one record per 
person, while the wound file held one record for each wound observation (several 
records per person).  Chi-square tests were conducted initially to ascertain any 
differences between the two treatment groups.  A Wilcoxon-2-sample test was used 
to analyse age and wound size at baseline due to skewed data. Data analysis was 
performed using Statistical Analysis Software (SAS) version 9.2 (SAS Institute 
Incorporated, Cary, NC, USA, 2008). 
 
The size of the wound at each time point was estimated by the multiplication of the 
wound length and depth. In usual circumstances, three dimensional measures, 
including length, depth and width are used for wound assessment. However, due to 
anatomical positioning and tissue curvature associated with wounds in the 
sacrococcygeal area accurate assessment of width was not possible and hence it 
was not measured. Single and two dimensional measurements have been utilised in 
other studies to predict wound healing (Marks et al.,1983). 
 
As well as the size of the wound, each wound observation included a variable 
indicating whether the wound had ‘healed’ or not.  From these observations, the time 
(days) to healing was able to be calculated. For the purpose of the study, the wound 
was classified as healed when there was 100% epithelialisation on the wound 
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surface.  The purpose of the analysis was to identify factors associated with changes 
in wound size and with wound healing. 
 
Differences in time to heal between the treatment groups (‘intention to treat’ as 
randomised) were examined by plotting a Kaplan Meier (KM). This is a univariate 
comparison as the KM curves cannot take into account any of the wound 
characteristics which may be associated with healing, for example, wound size. In 
order to take possible confounding variables into account for time to wound healing, 
a multivariate Cox proportional hazards regression was also conducted.  This 
analysis was able to examine the relationship between the primary outcome 
measure, days to heal and potential confounders/key covariates such as presence of 
infection, wound size at recruitment, co-morbidity index score and nutrition.  
 
The second analysis was a repeated measures regression to identify factors 
associated with changes in wound size over time.  This was implemented as a 
random effects regression model. Wound size measurement was skewed by some 
large measurements; hence a logarithmic transformation was applied to improve 
normality and the median and range was used to report results rather than the mean. 
This type of analysis was used so that the correlations between measurements on 
the same person could be taken into account.  The person identifier was named as 
the random effect. The percentage change in wound size from baseline to each time 
point was calculated, and used as the dependent variable. For the purpose of this 
regression model, the wound size was coded to zero when the wound was healed to 
enable application of the model to the whole dataset rather than only wounds which 
had not healed. All independent variables were initially included, and then the least 
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significant was dropped from the model one at a time, until all variables remaining in 
the model were statistically significant (p<0.05). Independent variables were: age, 
gender, dressing group, smoking, clinical signs of infection at baseline, presence of 
leucocytes at baseline, initial antibiotics (taken within the first 2 weeks) and 
occupation (manual or non-manual). 
 
It was planned that should there be significant numbers of clients whose treatment 
changed during the course of the study, the analyses would be repeated for the 
“actual treatment” groups.  This did not turn out to be necessary. 
 
Costs of the dressing groups were calculated using planned rather than actual costs. 
This method was adopted due to difficulties in determining the accuracy of data in 
regards to number of dressings used and time taken to perform each dressing 
change. Although Silver Chain captures actual service records for clients, it is a 
partly manual process and is subject to human error. Nursing staff are required to 
manually note the time they start and finish a client’s care, which is then entered 
onto the client data base against the respective client’s record.  Furthermore, the 
exact details and amount of wound products used are not directly linked to the client, 
so it is not possible to accurately track product usage in relation to individual clients. 
Electronic systems are currently under development at Silver Chain which will 
facilitate more accurate capture of care times and product use. This will not only 
provide accurate information for the organisation and funders but will also provide 
accurate assessment of care costs for future research projects. 
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The cost included the nursing time (hourly rate of nursing time averaged over a 7 
day period to take into account after-hour penalties) and dressing consumables 
(dressing pack, 0.9% sodium chloride sachet, the randomised silver alginate or 
calcium alginate dressing and the secondary absorbent dressing) were calculated 
per day and this was multiplied by the number of days the participant was on the 
study. The allocated dressing was used for two consecutive days. Each dressing had 
a portion used on the day of opening and the remainder was resealed in its original 
package for further use the following day. Any remaining dressing product after this 
time was disposed of. Costs for wound swabs were not included in the comparison, 
as this would not be considered a routine component of wound management for 
these clients.  
 
Ethical Procedures  
Permission to conduct this study was approved by the Silver Chain Human Research 
Ethics Committee and from the Human Research Ethics Committee at Curtin 
University. The study was conducted in accordance with the National Health and 
Medical Research Council ethical guidelines as stated in the National Statement on 
Ethical Conduct in Human Research 2007.  
 
Written consent was obtained from eligible participants after they had viewed the 
Study Information Sheet and agreed to participate.  The database was stored in the 
Research Directory on the Silver Chain network to which only members of the 
research team had access. The manufacturer’s of the dressing products, Smith & 
Nephew did not supply dressing products or provide any financial assistance for this 
study. 
41 
 
 
Conclusion 
This RCT was conducted within the metropolitan service centres of Silver Chain to 
investigate the efficacy of the prophylactic use of nanocrystalline silver alginate 
wound dressings promoting reduced healing times as compared to calcium alginate 
dressings in PSWs. It was calculated that each study group would require 44 
participants. Participants meeting the inclusion criteria were randomised to dressing 
groups and received daily wound care for the duration of their participation in the 
study. Data relating to the participant and the progress of the wound was collected 
and analysed using SAS. Ethics approval for the study was obtained from both 
Curtin University and Silver Chain Human Research Ethics Committee.  
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Chapter 4 
Results 
Introduction 
Participant recruitment occurred from September 2008 to February 2010. The initial 
plan was to recruit participants over a 12 month period, however the recruitment 
target had not been achieved within 12 months, so recruitment was extended for a 
further 3 months with an aim to achieve the target of 88 participants. During the 
recruitment phase of the study the tertiary hospitals in WA commenced Hospital-in 
the-Home Programs and as a result, referrals of clients with pilonidal sinus wounds 
to Silver Chain diminished. Despite meetings and discussions regarding the study 
with the tertiary hospitals the referrals to Silver Chain did not improve, with only three 
more participants being recruited in the additional 3 month period. Discussions 
between the researcher and university supervisors resulted in a decision to cease 
study recruitment.  
 
A total of 51 participants met the inclusion criteria and were admitted to the study. 
Random allocation to the treatment groups resulted in 28 participants in the silver 
alginate (SA) dressing group and 23 participants in the calcium alginate (CA) 
dressing group. All clients with at least two wound measurements, for whom a 
healing rate could be calculated, were included in the analysis.  All analyses were by 
intention to treat. One participant withdrew from the study due to personal reasons 
and two were lost to follow up as they were unable to be contacted following the 
initial assessment and recruitment. As a result a total of 48 participants were 
included in the analysis, 25 within the SA dressing group and 23 within the CA 
dressing group Figure 1. No adverse events occurred during the study period. 
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Demographic and Comorbidity Profile 
The descriptive statistics displayed in Table 1, show the distribution of people and 
their characteristics between the two dressing groups. The demographics and other 
characteristics of the two dressing groups were compared to assess their 
equivalence and identify any differences. The two dressing groups were found to be 
equivalent on potential confounders.   
 
The study included 69.4% male (n = 34) and 28.6% (n = 14) female participants. 
There was no significant difference (p = 0.24) in the gender distribution between the 
two dressing groups. There was 64% (n =16) male and 36% (n = 9) female in the SA 
dressing group and 78% (n = 18) male and 22% (n = 5) female in the CA dressing 
group (χ2 =1.18, DF=1, p=0.24). 
51 Clients randomly allocated to treatment 
groups 
23 Clients allocated to 
calcium alginate dressing 
28 Clients allocated to silver 
alginate dressing 
23 Included in analysis 25 Included in analysis 
No client withdrew/lost to 
follow up  
3 Clients withdrew/lost to 
follow up (insufficient data for 
analysis)  
Figure 1: Participant Flowchart  
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The age of participants across both dressing groups ranged from 16-38 years, with a 
mean age of 22.2 years for all participants. The mean age for males across both 
dressing groups was 22.7 years and the mean age for females across both dressing 
groups was 21.1 years. There was no significant difference identified in relation to 
age between the dressing groups (z = 29, df = 46, p = 0.77), with an age range in the 
SA dressing group of 16-30 years, resulting in a mean age of 21.8 years and an age 
range in the CA dressing group of 16 – 38 years, resulting in a mean age of 22.7 
years.   
 
There was no significant difference relating to the country of birth of participants 
between the groups (df = 2, p = 1.0). Within the SA dressing group 77% (n = 17) of 
participants were born in Australia, 9% (n = 2) in the United Kingdom and 14% (n = 
3) from other countries. Within the CA dressing group 78% (n = 18) of the 
participants were born in Australia, 4% (n = 1) in the United Kingdom and 17% (n = 
4) in other countries. 
 
As anticipated with a young population, the participants performed well on the 
Charlson Comorbidity Index (CCI), where zero indicates excellent health and 37 
indicates poor health. There was no significant difference between the dressing 
groups on this index (df = 1, p = 1.0): 96% (n = 24) of participants in the SA dressing 
group had a score of zero and 100% (n = 21) of participants in the CA dressing 
group had a score of zero. One participant (4%) within the SA dressing group 
reported a co-morbid condition of gastro-oesophageal reflux disease. 
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The risk of malnutrition amongst the study sample was low with a mean score of 
0.17 on the Home and Community Care (HACC) Nutritional Risk Screening and 
Monitoring Tool for which a score of zero indicates no risk and a score of 11 
indicates high risk. The most common nutritional concern was reduced appetite at 
time of admission to Silver Chain with 6% (n = 3) of participants across both dressing 
groups experiencing this problem. There was no significant difference (df = 1, 
p=0.39) between the dressing groups relating to nutrition with 92% (n = 23) of the SA 
group scoring zero and 81% (n = 17) of the CA group scoring zero.  
 
Smokers accounted for 33% (n = 16) of the participants. There was no significant 
difference between the treatment groups for current smokers (χ2 = 0.92, DF = 1, p = 
0.34). Within the SA dressing group 29% (n = 7) of participants were smokers and 
43% (n = 9) of the CA dressing group were smokers. 
 
During study participation the majority of participants (82%) reported being either 
employed or engaged in full time studies. Only 18% of participants were identified as 
being unemployed, 4% (n = 1) in the SA dressing group and 14% (n = 3) in the CA 
dressing group. Students accounted for 37% (n = 9) of the SA dressing group and 
18% (n = 4) of the CA dressing group. Tradesmen (refers to males and females) 
accounted for 33% (n = 8) of the SA dressing group and 32% (n = 7) of the CA 
dressing group. Other occupations identified were retail industry workers 4% (n = 1) 
for SA dressing group and 14% (n = 3) CA dressing group, office based workers 8% 
(n = 2) for SA dressing group and 23% (n = 5) for CA dressing group, and other 
occupations accounted for 12% (n = 34) for SA dressing group and none for the CA 
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dressing group. There was no significant difference relating to occupation group (df = 
5, p = 0.17). 
 
Occupation was further classified into manual and non-manual labour based on the 
occupational activity of the employment. Non-manual labour (full time study and 
office work) was the most common type of employment activity with 67% (n = 16) of 
participants in the SA dressing group and 68% (n = 15) of the CA dressing group. 
Those employed in occupations that comprised manual labour were identified to be 
33% (n = 8) of the SA group and 32% (n = 7) of the CA dressing group. There was 
no significant difference between non-manual and manual occupational activities (χ2 
= 0.01, DF = 1, p = 0.92).  
 
The surgical procedure used to treat the participants’ pilonidal sinus disease was not 
shown to have a significant difference between the dressing groups (χ2 0.25, df = 4, p 
= 0.60). Two surgical procedures were performed and they were incision and 
drainage of pilonidal abscess and excision of pilonidal sinus. Incision and drainage 
was performed on 72% (n = 18) of the SA dressing group and 78% (n = 18) of the 
CA dressing group. Excision was performed on 28% (n = 7) of the SA dressing group 
and 22% (n = 5) of the CA dressing group. 
 
The shape of the post-operative wound was identified as having a narrow base or 
wide base. The narrow based wounds resulting from incision and drainage of 
pilonidal abscesses, whilst the wide based wounds resulted from excision of a 
pilonidal sinus. Overall, there was no significant difference identified pertaining to 
wound shape (χ2 = 1.31, DF = 1, p = 0.25). Narrow wound bases were identified for 
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60% (n = 15) of participants in the SA dressing group and 44% (n = 10) of the CA 
dressing group. Wide wound bases were identified for 40% (n = 10) of the SA 
dressing group and 57% (n = 13) of the CA dressing group. 
 
It was not possible to perform statistical analysis on the participants’ use of 
antibiotics prior to surgery for their pilonidal sinus disease as there was too much 
missing data in relation to this question. However, there was no significant difference 
(χ2 = 2.01, DF 1, p = 0.15) between the groups for antibiotic usage in the first two 
weeks post-surgery with 72% (n = 18) of the SA dressing group and 52% (n = 12) of 
the CA dressing group reported as taking antibiotics during this time. 
 
A range of dressing products were reported as being used prior to participation in the 
study and this was not shown to have a significant effect (Fishers exact, df = 4, p = 
0.60) on the outcome of the study. The most commonly reported dressing in use was 
calcium alginate, with 67% (n = 16) of the participants in the SA dressing group and 
80% (n = 16) of the participants in the CA dressing using this product prior to study 
commencement. This was followed by saline-soaked gauze which was used by 17% 
(n = 4) of the SA dressing group and 5% (n = 1) of the CA dressing group.  
 
The baseline median wound size was not found to be significantly different between 
the treatment groups, with the median wound size of 644mm2 for the SA dressing 
group and 900mm2 for the CA dressing group (z = 1.07, df = 46, p=0.29). 
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Table 1: Characteristics of Study Participants (p-values were obtained from the 
Chi-square test unless marked otherwise). 
 
Variable Silver Alginate 
(N=25) 
Calcium Alginate 
(N=23) 
      p-value 
Gender 
 Male 
 Female 
 
16 (64%)  
9 (36%) 
 
18 (78%)  
5 (22%) 
0.28 
Age (mean, range) § 21.8 (16 to 30) 22.7 (16 to 38) 0.77 
Nationality* 
 Australia 
 UK 
 Other 
 
17 (77%)  
2 (9%)  
3 (14%) 
 
18 (78%)  
1 (4%)  
4 (17%) 
1.0 
Surgical procedures 
Incision & drainage 
Excision  
 
18 (72%)  
7 (28%) 
 
18 (78%)  
5 (22%) 
0.62 
Occupation group* 
 Retail 
 Trade 
 Office 
 Student 
 Other 
 Unemployed 
 
1 (4%)  
8 (33%)  
2 (8%)  
9 (37%)  
3 (12%)  
1 (4%) 
 
3 (14%)  
7 (32%)  
5 (23%)  
4 (18%)  
0 
3 (14%) 
0.17 
Occupation activity 
 Non-manual 
 Manual 
 
16 (67%)  
8 (33%) 
 
15 (68%)  
7 (32%) 
0.92 
Wound shape 
 Narrow 
 Wide base 
 
15 (60%)  
10 (40%) 
 
10 (44%)  
13 (57%) 
0.25 
Current smoking 
 Yes 
 No 
 
7 (29%)  
17 (71%) 
 
9 (43%)  
12 (57%) 
0.34 
Nutritional risk score* 
 0 
 1 or 2 
 
23 (92%)  
2 (8%) 
 
17 (81%)  
4 (19%) 
0.39 
CCI score* 
 0 
 1 
 
24 (96%)  
1 (4%) 
 
21 (100%) 
0 
1.0 
Antibiotics taken prior 
to surgery 
 Yes 
 No 
 
 
12 (86%)  
2 (14%) 
 
 
5 (42%)  
7 (58%) 
Statistical analysis not 
interpretable, due to 
missing data 
Antibiotics in first 2 
weeks post-op 
 Yes 
 No 
 
 
18 (72%)  
7 (28%) 
 
 
12 (52%)  
11 (48%) 
0.15 
Dressing before study* 
 Saline soaked gauze 
 Hydrogel 
 Alginate 
 Hydro fibre 
 Other 
 
4 (17%)  
1 (4%)  
16 (67%)  
2 (8%)  
1 (4%) 
 
1 (5%) 
0 
16 (80%) 
3 (15%) 
0 
0.60 
Wound size at baseline 
(median and range) § 
644 (18 to 3150) 900 (54 to 6600) 0.29 
* p-value calculated from Fisher’s Exact Test 
§ p-value calculated from the Wilcoxon 2-sample test (non-parametric) 
 
 
49 
 
Time (Days) to Wound Healing 
The first analysis in relation to wound healing was undertaken to identify if there was 
any difference in the proportion of wounds that healed during the study between 
dressing groups.  
 
Table 2: Total Number of Wounds Healed 
Dressing Group p-value  
(Chi-square) 
Silver Alginate 
(N = 25) 
Calcium Alginate 
(N = 23) 
 
0.0806 15 (60%) 8 (35%) 
 
The total number of wounds healed between dressing groups is shown in Table 2, 
there was no statistical significance in the total number of wounds healed during the 
study period (χ2 = 3.05, DF = 1, p = 0.0806). 
 
Further analysis sought to determine any difference between treatment groups in the 
time to wound healing. The Kaplan-Meier (KM) curves were constructed for time to 
wound healing for each dressing group and these were then compared using the 
Log-rank test.   
 
The Log-rank test to compare the KM curves for the different dressing groups 
displayed in Figure 2 showed no significant difference between groups (χ2 = 1.94, df 
= 1, p = 0.1636).  The SA dressing group had a shorter time to wound healing with a 
median of 46 days (95% CI = 33-61) as compared to 66 days (95% CI: 50-89) for the 
CA dressing group, but this was not statistically significant.  Due to the relatively 
small numbers of participants, the difference in time to wound healing would need to 
be larger in order to be statistically detectable (with α = 0.05).  
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The Cox proportional hazards model displayed in Table 3, also showed no significant 
difference between dressing groups (p = 0.53) after adjustment for initial wound size 
and other wound and person characteristics. 
 
 
 
 
 
 
 
Figure 2:  Kaplan Meir Survival Curves 
 
Silver Alginate         
Calcium Alginate 
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Table 3:  Cox Proportional Hazards Model for Healed Wounds 
Variable Hazard Ratio 95% Confidence Interval p-value 
Dressing: 
  Silver alginate 
  Calcium alginate 
 
1 (reference) 
0.81 
 
 
0.43 to 1.55 
 
 
0.53 
Initial wound size: 
  Small (<=377mm2) 
  Medium (377-1200mm2) 
  Large (1200+mm2) 
 
4.36 
1 (ref) 
0.36 
 
1.90 to 9.98 
 
0.15 to 0.87 
 
0.0005 
 
0.0227 
 
Overall, the initial wound size was the only variable which was found to be 
significantly associated with time to wound healing.  When compared to medium 
sized wounds, the smaller wounds healed significantly quicker (p = 0.0005, Hazards 
Ratio (HR) > 1 indicated a greater chance of healing), while the larger wounds were 
significantly slower to heal (p = 0.0227, HR < 1).  The dressing type variable was 
added into the model, and found not to be associated with wound healing. Similarly, 
the other variables: age, gender, smoking, clinical signs of infection, presence of 
leucocytes at baseline, initial antibiotics (taken within the first 2 weeks) and 
occupation (manual or non-manual) were not found to have a significant relationship 
with wound healing. 
 
Changes in Wound Size Over Time 
It was found that the wound size measurement was not normally distributed (skewed 
by some large measurements in some wounds), and hence a logarithmic 
transformation was applied to improve normality.  After adjustment for the highly 
significant (F1,337 = 111.5, p = <0.0001) change in wound size over time (days from 
baseline), the wound size reduction appeared to be significantly associated with the 
dressing group (F1,337 = 5.9, p = 0.0160), and the presence of leucocytes at 
baseline (F1,337 = 22.7, p = <0.0001). It appeared that the SA dressing group was 
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associated with a significantly faster wound size reduction over time as compared to 
the CA dressing group as displayed in Figure 3 and Table 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:  Change in Wound Size Over Time (Black line = SA dressing group, red 
line = CA dressing group. Dots = individual participant measurements; lines = 
median measurements at each week. Wounds classified as healed are not 
included). 
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Table 4:  Change in Wound Size Over Time 
Week Silver Alginate 
(N=25) 
Calcium Alginate 
(N=23) 
 Number of 
Healed Wounds 
(accumulative 
total) 
Size as % of 
baseline (range) 
Number of 
Healed Wounds 
(accumulative 
total) 
Size as % of 
baseline (range) 
1 0 65.2 (14.0 to 333.3) 0 71.2 (15.0 to 100.0) 
2 1 33.1 (7.0 to 95.7) 1 50.0 (5.6 to 527.8) 
3 3 13.7 (1.6 to 59.3) 1 41.7 (7.9 to 311.1) 
4 4 7.2 (0.1 to 51.1) 1 35.7 (3.8 to 259.3) 
8 15 4.2 (0.4 to 14.8) 8 11.5 (1.9 to 37.5) 
 
Table 4 shows the change in wound size over time, the weekly values for the median 
wound size and range are expressed as a percentage of the baseline value for 
unhealed wounds, for each dressing type. The median and range were used due to 
skewed wound measurement data. Participants with healed wounds were excluded 
from the size calculations as they healed. The results appear to demonstrate a more 
rapid healing rate for the SA dressing group as compared to the CA dressing group.  
 
Table 5: Percentage Change in Wound Size from Baseline (using all data up to 
week 8).   
Variable Coefficient (95% CI) *LS Mean (95% CI) p-value 
Dressing 
 Silver alginate 
 Calcium alginate 
 
-19.7 (-35.9 to -3.5) 
0 (reference) 
 
28.7 (17.7 to 39.7) 
48.4 (36.6 to 60.2) 
0.0170 
Week number  -11.6 (-13.1 to -10.0)  <0.0001 
*The Least Squares (LS) mean is a mean percentage of wound size averaged 
across all the weeks of the study, which gives an indication of the difference between 
dressing groups. 
 
A random effects regression model was used to identify factors associated with the 
percentage change in wound size from baseline as displayed in Table 5. Overall, for 
each week of the study, it appeared that the wound size reduced on average by 
11.6% from baseline.  However, the SA dressing appeared to result in smaller 
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wound sizes than the CA dressing at each time point. The average change of wound 
size from baseline was approximately 20% greater with the SA dressing group than 
the CA dressing group.  
 
Further analysis was conducted to explore the trend that silver containing dressings 
result in faster wound healing in the first 2 weeks of use, which has been 
demonstrated in other studies (Miller et al, 2010). The random effects model was 
therefore applied to the dataset in stages: 0-2 weeks and 3-8 weeks.  The dependent 
variable for the 0-2 week period was the same as above (percentage change in 
wound size from baseline).  However, the dependent variable for the second period 
(3-8 weeks) was the percentage change in wound size from week 2.  The purpose of 
this analysis was to compare the changes from week 3 onwards, essentially 
disregarding any differences that may have appeared up to week 2.  The results are 
shown in Table 6. 
 
Table 6: Percentage Change in Wound Size Between Baseline-2 Weeks and 
Weeks 3-8 
Time Period Variable Coefficient (95% CI) LS Mean (95% CI) p-value 
Baseline-2 
weeks 
Dressing: 
 Silver alginate 
 Calcium alginate 
 
-15.4 (-35.4 to 4.6) 
0 (reference) 
 
66.8 (53.3 to 80.3) 
82.2 (67.5 to 96.9) 
0.1290 
 Week number -24.2 (-35.3 to -13.2)  <0.0001 
3-8 weeks Dressing: 
 Silver alginate 
 Calcium alginate 
 
-14.2 (-40.8 to 12.3) 
0 (reference) 
 
46.9 (29.2 to 64.6) 
61.1 (41.3 to 81.0) 
0.2915 
 Week number -16.2 (-21.0 to -11.3)  <0.0001 
 
Overall, there was a very significant change in wound size over the first 2 weeks 
amongst participants (24% reduction from baseline per week).  However, the 
difference between the dressing groups, whilst suggestive of an advantage for SA, 
was not statistically significant (p = 0.13).  Overall the reduction in wound size from 
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week 3 onwards was less than the first 2 weeks (16% reduction from week 2) and 
the dressing group remained not significant, although there was still a suggestion 
that the SA dressing group had greater wound size reduction as compared to the CA 
dressing group.  
 
Wound Swabs 
Wound swabs were collected from participants at recruitment and during weeks 4 
and 8 of the study period if the wound remained unhealed. The swabs were sent for 
laboratory analysis for microscopic culture and sensitivity. Many of the participants 
had healed wounds prior to week 4; therefore only one swab was available for these 
participants, which limited overall comparative analysis. Analysis was further limited 
due to missing data, small numbers and varying reporting methods from the 
pathology company used to analyse the wound swabs. This resulted in difficulties in 
determining the antimicrobial effectiveness of the nanocrystalline silver alginate 
dressing.  A total of 99 swabs were collected from 48 participants during the study 
period as presented in Table 7 and the descriptive pathology is displayed in Table 8. 
 
Table 7: Total Number of Swabs Collected 
Data Collection Point Number of Participants Number of Swabs  
Recruitment 48 47 
Week 4 37 36 
Week 8 18 16 
Total   99 
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Table 8: Descriptive Pathology Data (numbers in the cells are the number of 
cases) 
 
Variable Silver Alginate 
(N=25) 
Calcium Alginate 
(N=23) 
 Week 0 Week 4  Week 8 Week 0 Week 4 Week 8 
Leucocytes 
Missing/NR* 
Not seen 
Occasional 
+ 
++ 
+++ 
 
0 
2 
5 
7 
7 
4 
 
6 
9 
4 
2 
4 
0 
 
18 
3 
0 
1 
2 
1 
 
2 
0 
6 
7 
4 
4 
 
8 
0 
2 
8 
2 
3 
 
13 
3 
3 
1 
1 
2 
Bacteria 
Missing/NR 
Not seen 
 
7 
18 
 
12 
13 
 
22 
3 
 
14 
9 
 
18 
5 
 
19 
4 
Gram Positive Cocci 
Missing/NR 
Occasional 
Some (+ or more) 
 
22 
2 
1 
 
21 
3 
1 
 
22 
1 
2 
 
13 
10 
0 
 
14 
6 
3 
 
19 
2 
2 
Gram Positive Bacilli 
  Missing/NR 
  Occasional 
  Some (+ or more) 
 
20 
4 
1 
 
25 
0 
0 
 
23 
2 
0 
 
17 
4 
2 
 
20 
2 
1 
 
21 
1 
1 
Gram Negative 
Bacilli 
  Missing/NR 
  Occasional 
  Some (+ or more) 
 
22 
3 
0 
 
24 
1 
0 
 
24 
0 
1 
 
19 
1 
3 
 
22 
1 
0 
 
22 
1 
0 
*NR= not reported 
 
 
The most frequent pathogen isolated from wound swabs was staphylococcus 
aureus. At recruitment it was isolated in 4% (n = 1) of the SA dressing group and 
17% (n = 4) of the CA dressing group. At 4 weeks it was isolated in 16% (n = 4) of 
the SA dressing group and 26% (n = 6) of the CA dressing group and at 8 weeks 
20% (n = 5) of the SA dressing group and 30% (n = 7) of the CA dressing group. 
Mixed coliforms were isolated in 8% (n = 2) of the SA dressing group at recruitment 
with none isolated in weeks 4 and 8. In the CA dressing group, mixed coliforms were 
isolated in 17% (n = 4) at recruitment, 4% (n = 1) at week 4 and none at week 8. The 
frequency of organisms identified from the wound swabs is displayed in Table 9.   
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Table 9: Number of Wounds in Which Micro-organisms are Present 
 
Variable Silver Alginate 
(N=25) 
Calcium Alginate 
(N=23) 
 Week 0 Week 4  Week 8 Week 0 Week 4 Week 8 
MA 2    1 1 
MColi 2   4 1 0 
SA 1 4 5 5 6 7 
SMI   1  1 1 
STRB   1 1 2 1 
STRG 1 1 1 1   
No of organisms 
 None 
 1 
 2 or more 
 
19  
6 
0 
 
21 
3 
1 
 
19 
4 
2 
 
12 
11 
0 
 
12 
11 
0 
 
13 
10 
0 
Legend: MA = Mixed anaerobes, MColi = Mixed Coliforms, SA = Staphylococcus 
Aureus, SMI =Streptococcus Milleri , STRB = Streptococcus B, STRG = 
Streptococcus G. 
 
 
The number of wounds with organisms between dressing groups was compared at 
each swab collection point to see if there was any difference in the number of micro-
organisms over the study period. The results are displayed in Table 10. The p-values 
were obtained from Chi-square tests (statistic is shown).  All tests were based on 1 
degree of freedom (no organisms vs some organisms) 
 
Table 10: Number of Wounds with Micro-organisms at Each Swab Collection 
Point. 
 
Week Silver Alginate Calcium Alginate p-value (Chi-square) 
0  6  11 0.0847 
4  4  11 0.0175 
8 6  10 0.1527 
 
There was no significant difference between the groups at recruitment in relation to 
the isolation of micro-organisms from wound swabs, the SA dressing group had 24% 
(n = 6) participants with micro-organisms isolated from wound swabs, as compared 
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to 47% (n = 11) of the CA dressing group (χ2 = 2.97, DF = 1, p = 0.0847).  At week 4, 
there was a statistically significant difference between the groups in relation to the 
presence of micro-organisms isolated from wound swabs (χ2 = 5.65, DF = 1, p = 
0.0175), however as the numbers were relatively low the significance of this may be 
inaccurate. At week 8, again there was no statistical significance between the 
proportion of wounds in each dressing group with micro-organisms isolated from 
wound swabs (χ2 = 2.05, DF = 1, p = 0.1527).  
 
The participants that had micro-organisms identified from their wounds were 
reviewed for clinical signs of overt or covert infection at the time the swab was 
collected. The clinical signs of infection identified were purulent exudate, changes in 
granulation tissue, erythema, localised heat, increased or new pain and malodour as 
displayed in Table 11. Participants may have had more than one clinical sign of 
infection.  
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Table 11: Clinical Signs of Overt or Covert Infection at Time of Swab Collection 
 
Pathogen *  Clinical Signs of Infection 
Present** 
No of Cases 
with 
Reported 
Clinical 
Signs of 
Infection & 
Pathogen 
Total No 
of Cases 
with 
Pathogens 
Identified 
Staphylococcus 
aureus 
• Changes in granulation 
tissue*** 
• Erythema 
• Localised heat 
• Increased pain 
• Purulence 
7 28 
Streptococcus G • Malodour 1 4 
Streptococcus B • Nil 0 5 
Mixed Coliforms  
 
• Changes in granulation tissue 
• Erythema 
6 7 
Streptococcus 
Milleri 
• Changes in granulation tissue 
• Increased pain 
1 3 
Mixed Anaerobes • Changes in granulation tissue 2 4 
*Participants may have had more than one pathogen isolated. 
* * Participants may have had more than one clinical sign of infection.  
***Changes in granulation tissue included bright red, friable, bridging and/or 
hypergranulation.  
 
As it was not possible to ascertain the antibacterial effectiveness of the 
nanocrystalline silver alginate dressing due to the reduced number of participants 
under study and the limited data obtained, an independent microbiologist was asked 
to review the results to ascertain any clinical significance and none was reported. 
 
Costs 
The mean cost per participant between the two groups was not statistically 
significant when analysed (t = 0.57, df = 46, p = 0.5697), as shown in Table 12.  
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Table 12: Costs for all Participants (Nursing Time & Consumables) 
Dressing Group Daily Cost Mean Cost per 
Participant 
p-value  
(t-test) 
Silver Alginate  $78.64 $3337.50 
 
0.5697 
Calcium Alginate  $69.28 $3168.80 
 
 
The daily cost per participant was lower for the CA dressing group than the SA 
dressing group. However, although not a significant finding, the mean cost per 
participant for the length of study participation (healed and non-healed wounds) was 
marginally less for the SA dressing group due to the reduced number of days the SA 
dressing group participants were under study.  
 
Table 13: Cost for Healed Wounds (Nursing Time and Consumables) 
Dressing 
Group 
Number of 
Healed 
Wounds  
Mean Cost per 
Participant for 
Healed Wound 
p-value 
(t-test) 
Silver Alginate 15(60%) $2752.40 0.9358  
Calcium 
Alginate 
 8 (35%) $2719.20 
 
The cost to achieve wound healing was compared for both dressing groups and no 
statistical significance was found in relation to cost for wounds that healed (t = 0.08, 
df = 21, p = 0.9358).  
 
 
Conclusion 
The study was not able to demonstrate a statistically significant difference in time to 
wound healing between dressing groups using either a univariate (KM analysis) or 
multivariate analysis (Cox model), and this was possibly due to the relatively small 
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number of participants enrolled in the study.  However, after adjustment for 
covariates, the random effects regression model demonstrated a significantly faster 
reduction in wound size in the SA dressing group as compared to the CA dressing 
group. Wound swab analysis identified several different pathogens present in the 
pilonidal sinus wounds; however due to limitations with analysis the significance of 
these in relation to wound healing was not able to be demonstrated.  There was no 
significant difference found in relation to cost of care for all participants and for 
healed wounds between the dressing groups.  
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Chapter 5 
Discussion 
Introduction 
The aim for pilonidal sinus wounds healing by secondary intention is to achieve 
controlled closure of the wound in a timely manner and to minimise the risk of 
infection and recurrence. The anatomical location and nature of PSWs predispose 
them to overt and covert infection which can result in delayed wound healing. The 
literature review revealed limited studies on the management of PSWs healing by 
secondary intention. Although, several different wound care products have been 
studied in relation to wound healing for PSWs, there was limited consideration given 
to the increased risk of infection of these wounds and there remains no consensus 
on the most appropriate management option.  This study sought to determine if the 
prophylactic use of nanocrystalline silver alginate dressings, in sacrococcygeal 
pilonidal sinus wounds would promote faster healing as compared to calcium 
alginate dressings.  
 
Wound Healing 
It was hypothesised that this study would show a faster wound healing rate with a 
silver alginate dressing as compared to a calcium alginate dressing for 
sacrococcygeal pilonidal sinus wounds healing by secondary intention. However, 
although the results suggested a trend for faster wound healing: 46 days with the SA 
dressing group as compared to 66 days with the CA dressing group, the difference 
was not statistically significant. A difference of this magnitude may however have 
been statistically significant in a larger study.  Overall, the analysis identified initial 
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wound size as the only variable which was statistically significant in relation to wound 
healing, that is smaller wounds were significantly faster than larger wounds to heal. 
 
Further analysis of wound healing identified that the change in wound size over time 
was significantly associated with the dressing group. The SA dressing group had on 
average a 20% better wound size reduction over the study period than the CA 
dressing group. Additionally, there was a higher percentage (60%, n = 15) of wounds 
healed in the SA dressing group than the CA dressing group (35%, n = 8).  
 
Additionally, comparison of percentage of change in wound size between baseline 
and week 2 and week 3-8, showed a rapid reduction in wound size in the initial 2 
weeks of study participation, and although not a significant finding this was better for 
the SA dressing group. This is a similar finding to Miller et al. (2010), who identified 
swifter wound healing in the first 2 weeks of treatment with a nanocrystalline silver 
dressing as compared to cadexomer iodine dressings for community patients with 
leg ulcers. Based on these findings, nanocrystalline silver alginate dressings would 
be an appropriate choice of dressing for sacrococcygeal PSWs healing by secondary 
intention. Further research is, however, required to explore these findings to 
determine if the improved healing rate is related to either the antimicrobial, anti-
inflammatory or pro-healing effects of the nanocrystalline silver or a combination of 
these properties. 
 
The presence of leucocytes at recruitment was also found to be associated with 
change in wound size over time. However, there was a significant amount of missing 
data relating to this, as leucocytes were not consistently reported by the laboratory. 
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Leucocytes are cells of the immune system which defend the body against infections 
and foreign materials; however they also aid the removal of damaged and devitalised 
tissue and play a role in the normal physiological process of wound healing (Carville, 
2012). As study recruitment occurred from day 2 to 7 post surgery, their presence in 
the wound could be related to normal physiological healing. The inflammatory phase 
of wound healing occurs from day 0 to 4 of wounding and involves an increase in 
localised blood flow and immune response. Inflammation presents clinically with 
erythema, oedema, exudate and pain (Carville, 2012). Wound infection can initiate 
an inflammatory response within the wound and can present clinically with similar 
signs.  
 
Identifying wound infection requires assessment of the person as well as the wound.  
Clinically it is based on signs and symptoms of the person, the wound and the 
surrounding skin (Sibbald & Ayello, 2007). Wounds contain bacteria soon after they 
occur, however, the potential for bacteria to produce harmful effects is influenced by 
the number and virulence of the bacteria and host resistance (Principles of Best 
Practice, 2008). Wounds can remain in bacterial balance when the wound is 
contaminated or colonised with organisms without causing tissue damage. However, 
this can progress to a bacterial imbalance, that is covert or overt infection, when a 
host response occurs (European Wound Management Association, 2006; Principles 
of Best Practice, 2008; Sibbald & Ayello, 2007). Classic signs and symptoms of 
infection are used to identify overt infection, however, signs of covert infection may 
be more difficult to identify, as the signs are not widely recognised (Gardner et al., 
2001). Differentiating overt and covert infection from a clinical aspect can be aided 
by the use of various tools and guidelines such as, Gardener et al., (2001) Clinical 
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Signs and Symptoms Checklist or NERDS and STONES mnemonics (Sibbald & 
Ayello, 2007). NERDS can aid diagnosis of superficial infection (Non healing, 
Exudative, Red and bleeding granulation tissue, Debris in the form of slough or 
necrotic tissue, Smell (from wound), whereas, STONES can aid diagnosis of deep 
tissue infection (Size is bigger, Temperature is increased, Os can probe to bone, 
New areas of breakdown, Exudate, erythema oedema, Smell from wound (Sibbald & 
Ayello, 2007). The authors suggest that when two or three of the signs for NERDS or 
STONES are present, a diagnosis of localised or deeper tissue infection can be 
made respectively.  
 
Not all participants that were identified as having organisms identified in wound 
swabs showed signs of overt or covert infection. In relation to Staphylococcus 
aureus, only seven (25%) of the 28 participants who had this organism isolated in 
wound swabs, showed clinical signs of infection at the time the wound swab was 
collected. This would support the theory related to wound bio-burden that identifies 
that contaminated or colonised wounds fail to initiate a host response and hence, 
have no clinical changes or signs of infection, whereas covert or overt wound 
infection will initiate a host response and clinical signs of infection will be evident 
(Principles of Best Practice, 2008).  
 
Recent research in relation to wound infection has focused on the presence of 
biofilms, which are communities of micro-organisms encased in a protective matrix 
and attached to the wound bed (Woo et al., 2008).  They have been found by 
electron microscopy to be present on 60% of chronic and 6% of acute wounds 
(Australian Wound Management Association, 2010).  Micro-organisms within biofilms 
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develop a tolerance to the immune system, antibiotics and topical antimicrobials 
thereby making them resistant to factors that would normally kill the microbe in its 
planktonic state (Woo et al., 2008).  Although biofilms were not a consideration when 
planning this study as little was known about them in relation to wound healing, 
emerging evidence suggests they can contribute to delayed wound healing 
(Australian Wound Management Association, 2010). It has been suggested, that a 
broad spectrum antimicrobial that kills rather than inhibits growth of micro-organisms 
is more appropriate for the prevention of biofilm formation, with the aim that the 
planktonic microbes would be killed prior to the formation of the biofilm (Phillips, 
Wolcott, Fletcher, & Schultz, 2010). The percentage of biofilms in acute wounds is 
reportedly low as compared to chronic wounds, which suggests that biofilms are 
more likely to develop the longer the wound is present. There is therefore a potential 
risk that PSWs healing by secondary intention would be at increased risk of biofilm 
formation due to the often lengthy healing times. However, further research is 
required to fully understand the potential role biofilms play in PSW healing.   
 
The silver alginate dressing used in the study was selected primarily to reduce 
potential confounders, as it was equivalent to the calcium alginate dressing apart 
from the silver component. However, consideration was given to current evidence 
and the product’s antimicrobial properties in relation to the concern regarding 
prophylactic use of topical antimicrobial agents in the development of resistant 
strains of bacteria. Although to date, there has been no reported evidence, 
demonstrating a link with bacterial resistance and the clinical use of modern silver 
dressings (Leaper, 2011). The risk of resistance from silver dressings can be 
minimised by utilising dressings with high levels of silver that facilitate a rapid 
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bactericidal effect (Ovington, 1999, 2001). The nanocrystalline dressing used in this 
study has been shown to sustain a high level of active silver cation of 70 to 100 parts 
per million (ppm) (Edwards-Jones, 2006; Leaper, 2011), which is three to five times 
higher than the levels required for a bactericidal effect (Edwards-Jones, 2006).  The 
prophylactic use of topical antiseptics to prevent wound infection is supported by 
international consensus (Principles of Best Practice, 2008), when there is an 
increased risk of infection. Pilonidal sinus wounds are at increased risk of infection 
as they are often associated with abscess formation (Wilson, 1995). The study 
results suggest that the majority of study participants, 72% (n = 18) in the SA 
dressing group and 78% (n = 18) in the CA dressing group presented clinically with a 
pilonidal abscess, as incision and drainage was the most common surgical 
procedure performed. Additionally, the sacrococcygeal area is in close proximity to 
the perineum, where large numbers of both Gram-positive and Gram-negative rods 
of faecal origin are present (Percival, Emanuel, Cutting, & Williams, 2012) thereby 
increasing the potential for wound infection.  
 
Although the diagnosis of bacterial imbalance is made clinically, wound swabs may 
be required to guide treatment decisions especially when systemic treatment is 
required (Healy & Freedman, 2006; Sibbald & Ayello, 2007). Multiple organisms 
were identified from participants’ wound swabs, including mixed anaerobes, mixed 
coliforms (including escherichia coli), Staphylococcus aureus, Streptococcus milleri, 
Streptococcus B, and Streptococcus G. This has some similarity to the most 
frequently isolated pathogens in surgical site infection (SSI) as stated in the Centres 
for Disease Control and Prevention Guideline: for the prevention of surgical site 
infection (1999), which has recognised Staphylococcus aureus, coagulase-negative 
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Staphylococci, Enterococcus, Escherichia coli, Pseudomonas aeruginosa, and 
Enterobacter as being the most common organisms  (Bowler, Duerden, & 
Armstrong, 2001). 
 
The most common organism identified from the wound was Staphylococcus aureus.  
The normal levels of bacteria on adult skin has been estimated at between 6 × 102 
and 2 × 106 bacteria/cm2 with Staphylococcus aureus, being a frequent isolate 
(Percival et al., 2012). Although it is only transiently carried on intact skin, 
approximately 30% of healthy adults are colonised with Staphylococcus aureus 
usually in the anterior nares, vagina and perianal area and it is a prominent pathogen 
in wound infections (Percival et al, 2012). It was observed that there was a higher 
percentage of Staphylococcus aureus isolated from wound swabs taken from 
participants in the calcium alginate dressing group as compared to the silver alginate 
dressing group. However, the significance of this observation was unable to be 
determined due to the low numbers. The total number of participants with micro-
organisms identified in wound swabs was compared between dressing groups at 
recruitment and weeks 4 and 8. Although a statistically significant difference was 
observed at week 4, indicating this was less for the SA dressing group, this may not 
be accurate due to the low numbers involved. Additionally, although not a statistically 
significant finding, the SA dressing group had a lower number of people with micro-
organisms on recruitment than the CA dressing group.  Further research is required 
to determine the micro-flora of PSWs healing by secondary intention and the in vivo 
bactericidal effect of nanocrystalline silver dressings in relation to Staphylococcus 
aureus.  
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It was anticipated that normal bowel flora would be the most frequent isolate from the 
wound swabs, due to wound locality and the presence of bowel flora in this area; 
however, mixed coliforms were present in the wounds of only 2 participants (8%) at 
recruitment of the SA dressing group and 4 participants (17%) at recruitment and 1 
(3%) participant at week 4 of the CA dressing group. It is postulated that the low 
level of bowel flora isolated in wound swabs could be related to study participants 
having a shower prior to wound dressing changes, especially as the highest 
incidence of bowel flora was isolated from wound swabs collected at time of 
recruitment. However, further research would be required to confirm this due to low 
numbers limiting analysis. 
 
Overall, 35% (n = 17) of study participants at recruitment, 41% (n = 15) at week 4 
and 87% (n = 14) at week 8 had microorganisms isolated in wound swabs. The 
increased percentage of bacteria identified in the wound swabs over time could 
potentially correlate with the increased length of time that the wound was present; 
however this requires further investigation to confirm this assumption and to 
determine the clinical significance of these findings relating to effect on wound 
healing. 
 
Participant Demographics 
The demographics of study participants were similar to what has been found in other 
studies. In relation to gender, there was 69.4% male and 28.6% female which 
matches others’ findings which indicated that PSD is 3-4 times more likely to occur in 
males than females (Harris & Holloway, 2012; Sondenaa et al., 1992; Surrell, 1994). 
The increased tendency for it to occur more frequently in males may be linked to the 
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amount and distribution of body hair on males as compared to females as increased 
incidence has also been reported in hirsute individuals (Dwight & Maloy, 1953; 
Holmes & Turner, 1969; Notaro, 2003).   
 
The age range of study participants was 16 – 38 years again reflecting findings in 
other studies that identified that pilonidal sinus disease is rare before puberty and 
after the age of 40 years (Miller & Harding, 2003). This study identified the average 
age of presentation for males as 22.7 years and for females of 21.1 years, which is 
similar to the average age of affected individuals in other studies. For example, 
Notaro (2003), identified an average age of presentation for males as 21 years and 
19 years for females.  
 
Banerjee (1999), reported that pilonidal sinus disease was more prevalent in persons 
of European origin than in those of Asian and African origin. Although no rationale 
was provided for this Buie and Curtis (1952) suggested it was linked to different hair 
characteristics and growth patterns. This study was not able to support this finding 
as the demographic data collected by Silver Chain in relation to ethnicity is ‘country 
of birth’, which does not identify true ethnicity. Australia has a diverse cultural 
background with over a quarter of the population (26%) being born overseas 
(Australian Bureau of Statistics, 2011). Although, 73% of study participants were 
identified as being born in Australia, they could be second or third generation 
Australians with either parents or grandparents being born overseas and hence 
having alternate ethnic characteristics.  The study did not show any significant 
difference between participants and their country of birth.  
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Costs of Care 
The findings of this study suggest, that the use of nanocrystalline silver alginate 
dressings for PSWs healing by secondary intention is a cost effective option. 
Although the daily cost of care was less for the CA dressing group, the faster rate of 
wound size reduction for the SA dressing group resulted in comparable costs for 
both groups.   
 
Limitations 
The study only included a small number of clients with sacrococcygeal pilonidal 
sinus wounds thereby limiting the statistical analysis.  
 
The study was limited to follow up of clients for 8 weeks and many of the wounds 
remained unhealed at this time. Had follow up occurred until wound healing was 
achieved for all participants, healing times between the groups may have been 
different. Additionally, due to the limited timeframe of the study it was not possible to 
establish rate of recurrence of PSD between the dressing groups.   
 
Although there are multiple topical antimicrobial wound dressings available that 
would be suitable to use on pilonidal sinus wounds, this study was not designed to 
assess the effectiveness of all these products. Establishing the effects of other broad 
spectrum topical antimicrobial agents for prophylactic use on sacrococcygeal 
pilonidal sinus wounds healing by secondary intention requires further investigation. 
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Recommendations 
This study was conducted on community clients with wounds healing by secondary 
intention following surgical intervention for sacrococcygeal pilonidal sinus disease. 
The recommendations therefore can only be specifically related to this cohort of 
individuals.  
 
There are ten recommendations that result from the findings of this study and they 
are: 
 
1. The principle recommendation that arose from the findings of this study is 
a need to repeat this study with a larger number of individuals 
incorporating Hospital-in-the-Home (HITH) programs.  
 
2. Prophylactic use of silver alginate dressings should be considered a 
suitable wound management option for PSWs in the sacrococcygeal area, 
when the wound is healing by secondary intention and when there is an 
increased risk of infection.  
 
3. Further study is required to establish the relationship of the bacterial 
burden and delayed healing in PSWs due to the small number of 
participants and the limitations with data analysis.  
 
4. Further investigation is required to ascertain the role of biofilm formation in 
PSWs and the relationship with wound healing.  
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5. Additional studies using other broad spectrum topical antiseptic wound 
products such as iodine preparations, wound honey and 
polyhexamethylene biguanide (PHMB) would ascertain whether it was the 
antimicrobial effect or the anti-inflammatory effects of the nanocrystalline 
silver that contributed to a faster wound size reduction and shorter healing 
time. 
6. Further studies are conducted to identify rate of recurrence of pilonidal 
sinus disease following the treatment of the PSW with nanocrystalline 
silver dressings.  
7. Further studies are conducted on validity and reliability of wound 
measurements to establish the most accurate and reliable method of 
wound measurement. 
8. Further study is undertaken to identify the correlation between clinical 
signs and symptoms of infection and pathology for the purposes for 
diagnosing wound infection. 
9. Future studies to examine in more detail the cost of treatment for PSD 
including the cost to achieve wound closure.  
10. It is also recommended that further studies incorporate other factors that 
may affect the healing rates of PSWs including number of operations the 
client has undergone for PSD, if the surgery was performed as an 
emergency or elective procedure and if the client is obese or developed 
infection during wound healing. 
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Although it is recommended that the study be repeated with a larger number of 
individuals, the recommendations that result from this study could, with all due care,  
be extrapolated to individuals with a sacrococcygeal pilonidal sinus wound healing 
by secondary intention until further study can be conducted. 
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Chapter 6 
 
Conclusion 
 
Sacrococcygeal PSWs are at increased risk of infection due to the anatomical 
location of the wound and the common presentation of abscess formation of this 
condition. It was hypothesised that the prophylactic use of a topical silver alginate 
dressing would result in faster healing of PSWs. Although a statistical significance 
could not be determined for time to wound healing between the groups, the SA 
dressing group demonstrated faster wound size reduction as compared to the CA 
dressing group.  
 
Silver alginate dressings were demonstrated to be comparable to the calcium 
alginate dressings in total cost of care for healed wounds.  
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Appendix l 
Curtin University School of Nursing and Midwifery 
Study Information Sheet 
 
Study Title: A Randomised Controlled Trial to determine the effectiveness of Nanocrystalline 
Silver compared to Calcium Alginate Dressings following surgical excision of a 
sacrococcygeal pilonidal sinus. 
 
Lay title:  A study to compare the effectiveness of a Silver dressing for the treatment of wounds 
following surgical removal of pilonidal sinus. 
 
You are being asked to participate in a research study.  Please take your time to read this information 
statement and the attached consent form, which if you agree to take part, you will be asked to sign.  
Please discuss any questions you may have about the project with the nurse, either on the telephone 
when she rings you to confirm when she will be visiting you or when she visits. 
 
What is this study about? 
 
Pilonidal sinus is a condition arising from an ingrown hair; usually this occurs at the base of the spine.  
This is known as the sacrococcygeal area.  Infection often develops which results in the formation of 
an abscess.  An operation may be required to remove the ingrown hair and drain the abscess.  After 
the operation, the patient will have a wound that will require dressings until it is fully healed. 
 
This study will compare the effectiveness of a topical nanocrystalline silver alginate dressing (Acticoat 
AbsorbentTM) when used to dress wounds resulting from surgical removal of pilonidal sinus against a 
calcium alginate dressing (AlgisiteTM) which is the usual treatment for this condition.  
 
Wounds almost always have some bacteria in them.  Bacteria often won’t have any negative effect on 
the wound, however, if there are too many bacteria in the wound, healing of the wound may slow 
down or infection may develop.  If this happens, dressings called antimicrobials are used.  Silver is an 
antimicrobial and dressings impregnated with silver are commonly used to treat wounds that are 
deemed to have high levels of bacteria.  The location of wounds following surgery for pilonidal sinus 
disease puts them at a higher risk of being contaminated by bacteria due to the bacteria that is 
normally present in the bowel.  The study aims to find out if the use of a silver dressing following 
surgery will prevent bacteria growing in the wound and speed up healing time compared to the 
traditional treatment of calcium alginate dressings, because we don’t know if one is better than the 
other. 
 
A randomised controlled trial, in which people are randomly assigned to receive one treatment rather 
than the other, is considered to be the best way of comparing two different treatments. 
 
Who is conducting the study? 
 
The project is being conducted by Margaret Edmondson who is employed by Silver Chain as a 
Clinical Nurse Specialist.  She is conducting the research as part of an academic degree, with 
support from Dr Keryln Carville, Associate Professor in Domiciliary Nursing and Dr Gill Lewin, Silver 
Chain Research Manager. 
 
Who is invited to participate? 
 
You are being asked to participate in this study because you have a wound resulting from surgical 
excision of pilonidal sinus. 
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What will happen if you agree to take part in the project? 
 
If you agree to participate in this study you will be asked some questions about yourself which will 
help us understand your wound and what sorts of things may affect its healing. You will be randomly 
allocated to one of the two treatment groups. The nurse treating your wound will see you to treat your 
wound just as she would in normal circumstances. Every week the nurse will assess the wound and 
photograph it, so that we can see how it is progressing.  To ensure your privacy, the nurse will ensure 
that this photo will not include any identifying marks.  
 
Your participation in the study will be for 8 weeks or until your wound heals, whichever happens 
sooner.  If you are allocated to the silver treatment group you will receive the silver impregnated 
dressing for the duration of the study.  If you are allocated to the calcium alginate treatment group 
you will receive this dressing for the duration of the study unless your wound shows signs of infection.  
If this occurs you will then receive the silver dressing until the signs of infection are no longer present 
when you will revert to the calcium alginate dressing..  
 
At the end of the study period we will ask you to complete a brief questionnaire.  This questionnaire 
will ask what you thought of the treatment you received.  We will provide you with a stamped, 
addressed envelope to return the questionnaire to us.  
 
We will, with your permission, inform your doctor, and any other health professionals involved in 
providing your wound care, that you are participating in this study.  We will also ask that they follow 
the study care plan if they need to dress your wound at any time during the study period. 
 
Risks and benefits 
 
There are no risks to you in taking part in this study as you will continue to have your wound 
managed just as you would normally.  The only difference in treatment is how the choice of dressing 
is made.  In the unlikely event that the dressing being used is found not to suit you, it will be changed, 
as is normal practice. 
 
The project may benefit other people in the future having wounds resulting from surgical excision of 
pilonidal sinus disease by helping us identify which, if either, dressing works best. 
 
 
Voluntary participation 
 
It is important for you to know that you do not have to take part in this project and if you decide not to 
be involved, the wound care and other services provided to you by Silver Chain now, or in the future, 
will in no way be affected.  If after agreeing, you either wish to stop the treatment you have been 
receiving or change your mind about being in the study, you may withdraw your consent at any time, 
simply by telling the nurse providing your care or by ringing Dawn Woods, Research Support Officer 
on 9201 6758.  We would then stop collecting the study information and if you wish to no longer be 
part of the study, destroy all project records containing your information. 
 
How will your privacy be protected? 
 
If you do decide to take part in the study, all information relating to you that is used as part of the 
study, and is not required by those providing your care will be kept strictly confidential.  To protect 
your privacy, your name will not be kept on any study data but will instead only be identified with an 
identification number.  The results of this study will be presented to Curtin University of Technology 
for acedemic assessment, reported at conferences and in journal articles but this will not involve the 
reporting of any personal information.  In accordance with national research guidelines, all study 
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records will be stored for seven years by the Research Department in a secure location and will then 
be destroyed.  
 
What if you have any concerns or a complaint about how the study is conducted? 
 
Approval for this study and its procedures has been given by both Silver Chain and  
Curtin University, Human Research Ethics Committees.  Any concerns or complaints about the 
conduct of the study should be directed to Dawn Woods, Research Support Officer on 9201 6758 or 
to the Chairperson of the Silver Chain Human Research Ethics Committee, Silver Chain House, 
6 Sundercombe Street, Osborne Park 6017.  
 
Who to contact if you have any questions about the study? 
If you have any questions about this study please discuss them with the nurse during your 
appointment.  Should you still wish to ask any further questions please feel free to call  
Margaret Edmondson, Clinical Nurse Specialist on 9242 0242 or Keryln Carville, 
Associate Professor of Domiciliary Nursing at Curtin University of Technology on 9242 0242. 
 
Thank you for taking the time to read this statement. 
 
Margaret Edmondson 
Clinical Nurse Specialist 
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Appendix ll 
Curtin University School of Nursing and Midwifery 
Study Consent Form 
 
Study Title: A Randomised Controlled Trial to determine the effectiveness of 
Nanocrystalline Silver Alginate Dressings compared with Calcium Alginate Dressings 
following surgical excision of a sacrococcygeal pilonidal sinus. 
 
Lay Title: A study to compare the effectiveness of a Silver dressing for the treatment of 
wounds following surgical removal of pilonidal sinus. 
 
Client Name:   _________________________________________________________  
 
Study Number:   _______________________________________________________  
 
Address:   ____________________________________________________________  
 
• I have read the Information Statement about this study and any questions I have asked 
have been answered to my satisfaction. 
 
• I agree to participate in this study, realising that I may withdraw at any time. 
 
• I agree that my general practitioner (GP) and other relevant health care professionals will 
be advised of my participation in this study and that if possible they should follow the study 
protocol when dressing my wound. 
 
• I agree to photographs of my wound being taken as part of this study and understand that 
they will not include any visually identifying information e.g. my face, a birthmark, tattoo etc.  
 
• I agree that information Silver Chain has collected during the process of providing my 
care may be linked with the data collected for this study, provided that I am not 
identifiable. 
 
• I agree that the research data (including wound photographs) collected for this study may 
be presented and published, provided that I am not identifiable. 
 
 
Signed:  ______________________________________________________  
 Participant/Authorised Representative/Parent  or Guardian  
    (for clients under 18 yrs) 
 
Name:  ______________________________________________________  
(PLEASE PRINT) 
 
Date:  ______________________________________________________  
 
Relationship if authorised representative:   ______________________________  
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Appendix lll 
Curtin University School or Nursing and Midwifery 
Initial Data Collection Form 
 
1 STUDY NUMBER:  _____________  ENVELOPE NUMBER:  _____________________   
 (client PID plus service centre initials e.g. SO for South) 
 
2 Date of recruitment  __ __ / __ __ / __ __ (dd/mm/yy) 
 
3 Date of surgery  __ __ / __ __ / __ __ (dd/mm/yy) 
 
4 Occupation (please specify)   ________________________________________________   
 
5 Type of surgical procedure performed (if known)   ________________________________   
 
6 Were antibiotics taken immediately prior to surgery? 
 
 1  Yes 2  No 
 
7 When did you have surgery following diagnosis of pilonidal sinus disease? 
 
 1  Within 48 hours 2  Within 2 weeks 3  Within 4 weeks  
 
 4  Over 4 weeks 
 
8 Is the wound shape:  1  V (narrow base) 2  U (wide base  
 
9 What dressing treatment is the client randomised to receive? 
 
 1  Acticoat Absorbent™  2  Algisite™ 
 
10 Wound dimensions 
 
 Length _____________mm Central Depth (perpendicular to skin) 
__________mm 
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11 Exudate Amount: 1  Nil  2  Low 3  Moderate 4  Heavy 
 
12 Exudate Type: 1  Serous  2  Haemoserous 3  Sanguinous 
 
  4  Purulent  5  Other  _______________________________   
 
13 Are any of the following evident in the wound or surrounding skin (tick all that apply)? 
 
 1  Increasing pain in the wound  7  Bright red granulation tissue 
 2  Erythema  8  Discolouration of granulation tissue 
 3  Oedema  9  Friable granulation tissue 
 4  Increased heat 10  Bridging of granulation tissue 
 5  Malodour 11  New wound breakdown 
 6  Increased amount of exudate 12  Hypergranulation tissue 
 
 
14 What was the most recent dressing regime before commencing the study treatment? 
 
  a) Primary b) Secondary 
 Saline soaked gauze  1  1  
 Non-adherent dry dressing  2  2  
 Tulle gras  3  3  
 Hydrogel  4  4  
 Alginate  5  5  
 Hydrofibre  6  6  
 Foam  7  7  
 Other (please specify)  8  8  
  _______________________________________________________________________   
 
 
MEDICATION HISTORY 
 
 
15 Has the client used any of the following in the last fortnight (tick all that apply)? 
 
 Antibiotics for wound  1  
 Drug  ________________________    Dose __________________ Route ___________   
 Start date _ _ / _ _ / _ _ (ddmmyy) _    Stop date _ _ / _ _ / _ _  (ddmmyy) 
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 Antibiotics for other reasons  2  
 Drug  ________________________    Dose __________________ Route ___________   
 Start date _ _ / _ _ / _ _ (ddmmyy) _    Stop date _ _ / _ _ / _ _  (ddmmyy) 
 
 NSAIDs  3  
 Anticoagulants  4  
 System steroids  5  
 Topical or inhalation steroids  6  
 Cytotoxics  7  
 Betablockers  8  
 Immunosuppressants  9  
 
 
CHARLSON COMORBIDITY INDEX 
 
 
16 Does the client have any of the following (tick all that apply)? 
 
 1  HIV AIDS   9  Leukaemia 
 2  Cerebrovascular disease 10  Lymphoedema 
 3  Chronic pulmonary disease 11  Malignant lymphoma 
 4  Congestive heart failure 12  Myocardial infarction 
 5  Connective tissue disease 13  Peripheral vascular disease 
 6  Dementia 14  Rheumatoid arthritis 
 7  Gastric ulcer disease 15  None of the above 
 8  Hemiplegia 
 
 
17 Is the client a current smoker?  1  Yes 2  No 
 
Does the client have any of the following? 
 
18 Liver disease? 1  None 2  Mild 3  Moderate 4  Severe 
 
19 Renal disease? 1  None 2  Mild 3  Moderate 4  Severe 
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20 Malignant 1  None 2  Non Metastatic 3  Metastatic 
 Solid tumour 
 
 
NUTRITIONAL RISK SCREEN TOOL 
 
 
21 Does the client have any 
 
 Obvious underweight frailty  1  
 Unintentional weight loss  2  
 Reduced appetite/food or fluid intake  3  
 Mouth or teeth problems   4  
 Swallowing problems   5  
 Follows a special diet   6  
 Needs assistance to shop for food  7  
 Needs assistance to prepare food  8  
 Needs assistance to deed self  9  
 Obvious overweight affecting life quality 10  
 Unintentional weight gain 11  
 
22 Please indicate the amount of time you spent at this visit attending to the care of the study 
ulcer (including setting up, providing and documenting care to study ulcer, excluding data 
collection, other treatment unrelated to the study ulcer). 
 
 1  0-15 minutes   2  16-30 minutes 3  31-45 minutes 
 4  46-60 minutes   5  61-90 minutes 6  >91 minutes 
 
23 Was a photograph taken at this visit? 1  Yes 2  No 
 
24 Additional Comments  ______________________________________________________   
  _______________________________________________________________________   
  _______________________________________________________________________   
 
 Name of Nurse completing form: 
 (Please print) 
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Appendix lV 
Curtin University School or Nursing and Midwifery 
Weekly Data Collection Form 
 
1 Client Study No:  ________________   (client PID plus service centre initials e.g. SO for South) 
 
2 Date  __ __ / __ __ / __ __ (dd/mm/yy)   
 
3 Study Week: 1  Week 1l  2  Week 2 3  Week 3 4  Week 4 
  5  Week 5  6  Week 6 7  Week 7 8  Week 8 
 
 
4 Wound Dimensions 
 
 Length _____________mm Central Depth (perpendicular to skin) 
__________mm 
 
5 How many visits to change the dressing for this wound have occurred in the last 
week (including this visit)?  ________________________________________________   
 
6 Has the study wound healed?  1  No  
    2  Yes  Date of healing _ _ / _ _ / _ _ 
(dd/mm/yy) 
    (if Yes go to question 10) 
 
7 Exudate Amount: 1  Nil  2  Low 3  Moderate 4  Heavy 
 
8 Exudate Type: 1  Serous  2  Haemoserous 3  Sanguinous 
  4  Purulent  5  Other  _______________________________   
 
9 Are any of the following evident in the wound or surrounding skin (tick all that 
apply)? 
 
 1  Increasing pain in the wound  7  Bright red granulation tissue 
 2  Erythema  8  Discolouration of granulation tissue 
 3  Oedema  9  Friable granulation tissue 
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 4  Increased heat 10  Bridging of granulation tissue 
 5  Malodour 11  New wound breakdown 
 6  Increased amount of exudate 12  Hypergranulation tissue 
 
 
COMPLETE THIS SECTION FOR ALL DRESSING CHANGES IN LAST WEEK 
 
 
10 How many of the study dressings were used at dressing changes in the last week 
(include today’s change).  Tick all that apply.  Please indicate the number and 
size/amount of each dressing used (e.g. 1 of 2cm x 30cm). 
 
 Acticoat absorbent: 1  Enter amount ______ 2cm x 30cm 
  2  Enter amount ______ Other, please specify  _____________   
 
 Algisite: 3  Enter amount ______ 2cm x 30cm 
  4  Enter amount ______ Other, please specify  _____________   
 
 
 
MEDICATION USE 
 
 
11 Has the client used any of the following in the last fortnight (tick all that apply)? 
 
 Antibiotics for wound  1  
 Drug  ________________________    Dose __________________ Route ___________   
 Start date _ _ / _ _ / _ _ (dd/mm/yy)    Stop date _ _ / _ _ / _ _  (dd/mm/yy) 
 
 Antibiotics for other reasons  2  
 Drug  ________________________    Dose __________________ Route ___________   
 Start date _ _ / _ _ / _ _ (dd/mm/yy)    Stop date _ _ / _ _ / _ _  (dd/mm/yy) 
 
 NSAIDs  3  
 Anticoagulants  4  
 System steroids  5  
 Topical or inhalation steroids  6  
 Cytotoxics  7  
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 Betablockers  8  
 Immunosuppressants  9  
 
 
CLIENT DISCHARGE 
 
 
12 Has the client been discharged since the last weekly assessment? 
 
 1  Yes 2  No (go to question 15) 
 
 Please write the date of discharge __ __/ __ __ / __ __ (dd/mm/yy) 
 
13 Please indicate the reason for discharge 
 
 Wound healed  1  
 Client moved to permanent care  2  
 Receiving terminal care  3  
 Client died  4  
 Client terminated care  5  
 Other (please specify)  6  
  _______________________________________________________________________   
 
14 Was the discharge related to the study wound? 
 
 1  Yes 2  No 
 
 Comments 
  _______________________________________________________________________   
 
 
 
CLIENT ON HOLD 
 
 
15 Has the client’s care been on hold since the last weekly assessment? 
 
 1  Yes 2  No (go to question 18) 
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 If yes, what was the reason? 
 Respite admission 1  In date:  __ __ / __ __ / __ __ (dd/mm/yy) 
   Out date: __ __ / __ __ / __ __ (dd/mm/yy) 
 
 Hospital admission 2  In date:  __ __ / __ __ / __ __ (dd/mm/yy) 
   Out date: __ __ / __ __ / __ __ (dd/mm/yy) 
 
 Holiday 3  In date:  __ __ / __ __ / __ __ (dd/mm/yy) 
   Out date: __ __ / __ __ / __ __ (dd/mm/yy) 
 
16 Was the respite or hospital admission related to the study wound? 
 
 1  Yes 2  No 
 
 If yes, please give details 
  _______________________________________________________________________   
 
17 Was the study treatment continued during the on hold period? 
 
 1  Yes 2  No  (If no, for how long was the study treatment NOT applied 
for?     ________________ days. 
 
 
USE OF STUDY DRESSING 
 
 
18 Has there been any change in the use of the allocated study dressing since the last 
weekly assessment (i.e. stopping, restarting or changing)? 
 
 1  Yes 2  No (go to Question 20) 
 
 Please write the date(s) that treatment changed 
 1:  __ __ / __ __ / __ __ (dd/mm/yy) 
 2:  __ __ / __ __ / __ __ (dd/mm/yy) 
 
19 Please confirm that the treatment was changed because 
     #1  #2 
 Adverse event to study dressing  1  1  
 Signs of infection in Algisite allocated client 2  2  
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 Critical infection in Algisite client now resolved 3  3  
 Client requested change in dressing  4  4  
 Other health professional requested change in dressing 5  5  
 Other (please specify)   6  6  
  _______________________________________________________________________   
 
 
 
ADHERENCE TO CARE PLAN 
 
 
20 Has the treatment care plan been adhered to since the last weekly assessment? 
 
 Yes    1  
 No – client did not adhere  2  
 No – Silver Chain staff did not adhere   3  
 No – other care provider did not adhere  4  
 No – other care provider did not adhere  5  
 No – other (please specify)   6  
  _______________________________________________________________________   
 
21 Please indicate the amount of time you spent at this visit attending to the care of the 
study wound (including setting up, providing and documenting care to study wound, 
excluding data collection and other treatment unrelated to the study wound). 
 
 1  0-15 minutes   2  16-30 minutes 3  31-45 minutes 
 4  46-60 minutes   5  61-90 minutes 6  >91 minutes 
 
22 Was a photograph taken at this visit?  1  Yes 2  No 
 
23 Additional Comments  ____________________________________________________   
  _______________________________________________________________________   
  _______________________________________________________________________   
 
 
 Name of Nurse completing form:  
 (Please print) 
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Appendix V 
Curtin University School or Nursing and Midwifery 
WOUND SWAB SPECIMEN COLLECTION FOR PILONIDAL SINUS STUDY 
 
Rationale 
• To collect a wound swab/specimen that minimises contamination by micro-organisms. 
• To use the most appropriate method for wound swab/specimen collection.  
• To understand the problems that normal flora can cause with wound swab/specimen 
collection. 
 
CliniPath Laboratory Requirements 
For the purpose of the Pilonidal Sinus Study 
 
1 Clinipath Pathology request forms, sterile wound swabs and biohazard collection plastic 
bags will be made available by Clinipath Pathology in all Silver Chain metropolitan 
service centres.  If you require extra supplies of the above, please call Chris on 
9476 5277. 
2 All laboratory costs will be paid by the Silver Chain.  This is not a Medicare rebateable 
item, nor are any costs incurred by the client. 
3 The RN/EN who takes the wound swab can sign the pathology request form (a doctor’s 
signature is not required). 
4 The pathology request form must be filled out in a legible manner ensuring that all 
necessary information is supplied.  Ensure that the pathology laboratory is provided with 
the following information: 
• Study number (PID / Base) 
• Identify on the form if the swab is the recruitment, week 4 or week 8 swab or tick 
other if it is before or after antibiotic therapy     
• Record on the client form: 
- full name 
- address 
- telephone number 
- sex 
- date of birth 
• wound site  
• date and time of specimen collection 
• record the name and address of the General Practitioner (GP) or surgeon so that 
a copy of the results can be sent by Clinipath Pathology to the treating doctor. 
101 
 
5 Add CNS’s name and email address so that an electronic copy of the results can be 
forwarded to the base. 
6 A completed pathology request form must accompany the collected specimen. 
 
Equipment 
• Disposable gloves if required 
• Sterile specimen swab stick in container 
• Sealable plastic biohazard bag with separate compartment for specimen collection 
request form 
• Clinipath Pathology request form 
• Sterile dressing pack 
• Sterile water sachet/s 
 
Procedure 
Note:  The wound swab is collected after washing wound as per care plan. 
 
1 Attend hand hygiene. 
2 Collect equipment 
3 Open dressing pack and pour a small amount of sterile water into one gallipot to be 
used to moisten the dry sterile specimen swab stick if required; pour remainder (or open 
additional sterile water) into the second gallipot for wound cleansing. 
4 Attend hand hygiene and don unsterile gloves if required 
5 Remove old dressing and discard appropriately. 
6 Use an aseptic technique to clean and dry wound.  Endeavour to remove remnants of 
dressing debris, visible exudate and loose devitalized tissue.  Do not contaminate the 
sterile water that may be used to moisten the sterile specimen swab stick. 
7 Carefully remove sterile wound swab from the container without touching the stick or 
wound contact surface. 
8 If the wound is dry moisten the dry swab stick in sterile water (not the water used to 
clean the wound) prior to swabbing the wound.  Swab the wound in a zigzag and rolling 
motion across the wound (Figure 1), but avoid contact with the wound edges.  
9 Reinsert the swab into the container, avoiding contamination by contact with external 
surfaces of the specimen container. 
10 Attend to dressing regime in accordance with the study protocol outlined on the care 
plan. 
11 Correctly label the specimen with: 
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- Silver Chain study number (PID / Base) including which number swab it is in the 
series. 
- client full name  
- date of birth  
- date and time of specimen collection  
- wound site 
12 Insert the specimen and completed paper work into the biohazard bag and place in the 
refrigerator.  Telephone Clinipath on 9476 5235 (Carly or Julie) and ask for a “Silver 
Chain pickup at (give either clinic or client’s address)”.  
13 Document in the client’s notes and study assessment form that the wound specimen 
has been collected and what number swab it is as per study protocol. 
 
Pathology Results 
1 The CNS should receive a PDF form detailing the results within 48 hours of collection.  
If not, please follow up with Margaret Edmondson on 92429242Clinipath on 9476 
5252. 
2 The pathology results are to be filed in the client’s notes. 
3 A copy of the pathology results will be sent by Clinipath to the treating doctor for his/her 
attention and action if required. Should the treating doctor choose to put the Client 
on antibiotics, the Client will remain on the study but please ensure details of 
antibiotics including starting and completion dates are entered onto data 
collection form. 
4 A copy of the pathology results will also be sent to the Silver Chain Research 
Department. 
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Figure 1: Zigzag Swab Method 
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Appendix Vl 
Curtin University School or Nursing and Midwifery 
Wound Photograph Protocol for Pilonidal Sinus Study 
 
Wound photographs are an essential part of the data collection process for the 
Pilonidal Sinus Study to verify anatomical location and clinical characteristics of the 
wound. 
 
When to Take Photographs 
• Initial first assessment and at weekly intervals (as part of data collection). 
• At the end of the 8 week study period or when wound heals (whichever is 
first).  
• If overt or covert infection necessitates the changing of client’s dressing from 
calcium alginate to nanocrystalline silver alginate dressings photographs 
shall be taken before and after. 
 
Specific Requirements 
• Informed consent must be obtained from the client and recorded on 
“consent to services form” in Home Notes, with date and client’s/carer’s 
signature. 
• Photographs should not identify participants, i.e. should not show faces, 
tattoos, etc. 
• Do not include client’s name within photo to ensure confidentiality. 
 
How to Take Photographs 
• Complete calibration label/sticker as follows: 
• Study number (PID/Base) 
• Date photo taken 
• Position calibration label on the skin, next to the wound, with the arrow on 
the label pointing to the person’s head and within the frame of the photo. 
• Take one photograph showing wound and anatomical location 
• Ensure plain background without any patterned sheets, carpets etc. 
• Position cameras ½ metre from and perpendicular (90 degrees) to the 
wound.  
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• Keep camera steady when photographing to ensure clear pictures and 
ensure wound image and writing is in focus prior to taking photo. 
 
If possible don’t use the flash but check the quality of the photo and take another if 
additional lighting required before sending. 
 
Subsequent photographs should be taken from the same angle and distance. 
 
Refer to camera’s user guide for further information. 
 
Useful Tips 
• Batteries for the camera should be inserted prior to use and removed 
afterwards as the camera continues to drain the batteries even when 
switched off.  Rechargeable batteries will be available at all bases. 
 
• Different models of digital cameras will operate differently; it is therefore 
essential to follow manufacturer’s instructions when using cameras and to 
get some practice with the camera prior to taking client photos.   
 
Where to Send the Memory Card 
Please write ‘PSS’ and your service centre on the memory card used for the trial and 
try to only use these memory cards for PSS photos. 
 
At the end of each week send memory card, in the plastic box provided, to: 
 
Gale Cargill 
Silver Chain 
6 Sundercombe Street  
Osborne Park WA 6017 
 
Images will be downloaded and deleted from the memory card which will be returned 
to the CNS at the Service Centre. 
 
Each camera has at least two memory cards and will hold up to 200 pictures. 
 
Please contact Margaret Edmondson Study Coordinator on 92420242 should you 
have any queries.  
